



## Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery

### Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Alessandro Brunelli, MD, FCCP; Anthony W. Kim, MD, FCCP; Kenneth I. Berger, MD, FCCP; and Doreen J. Addrizzo-Harris, MD, FCCP

**Background:** This section of the guidelines is intended to provide an evidence-based approach to the preoperative physiologic assessment of a patient being considered for surgical resection of lung cancer.

**Methods:** The current guidelines and medical literature applicable to this issue were identified by computerized search and were evaluated using standardized methods. Recommendations were framed using the approach described by the Guidelines Oversight Committee.

**Results:** The preoperative physiologic assessment should begin with a cardiovascular evaluation and spirometry to measure the FEV<sub>1</sub> and the diffusing capacity for carbon monoxide (DLCO). Predicted postoperative (PPO) lung functions should be calculated. If the % PPO FEV<sub>1</sub> and % PPO DLCO values are both > 60%, the patient is considered at low risk of anatomic lung resection, and no further tests are indicated. If either the % PPO FEV<sub>1</sub> or % PPO DLCO are within 60% and 30% predicted, a low technology exercise test should be performed as a screening test. If performance on the low technology exercise test is satisfactory (stair climbing altitude > 22 m or shuttle walk distance > 400 m), patients are regarded as at low risk of anatomic resection. A cardiopulmonary exercise test is indicated when the PPO FEV<sub>1</sub> or PPO DLCO (or both) are < 30% or when the performance of the stair-climbing test or the shuttle walk test is not satisfactory. A peak oxygen consumption ( $\dot{V}O_{2peak}$ ) < 10 mL/kg/min or 35% predicted indicates a high risk of mortality and long-term disability for major anatomic resection. Conversely, a  $\dot{V}O_{2peak}$  > 20 mL/kg/min or 75% predicted indicates a low risk.

**Conclusions:** A careful preoperative physiologic assessment is useful for identifying those patients at increased risk with standard lung cancer resection and for enabling an informed decision by the patient about the appropriate therapeutic approach to treating his or her lung cancer. This preoperative risk assessment must be placed in the context that surgery for early-stage lung cancer is the most effective currently available treatment of this disease.

*CHEST 2013; 143(5)(Suppl):e166S–e190S*

**Abbreviations:** ACCP = American College of Chest Physicians; CPET = cardiopulmonary exercise test; DLCO = diffusing capacity for carbon monoxide; ERS = European Respiratory Society; ESTS = European Society of Thoracic Surgeons; LVRS = lung volume reduction surgery; PICO = population, intervention, comparator or control group, outcome; % PPO = percent predicted postoperative; PPO = predicted postoperative; RCRI = revised cardiac risk index; STS = Society of Thoracic Surgeons; SWT = shuttle walk test; ThRCRI = thoracic revised cardiac risk index; VATS = video-assisted thoracic surgery;  $\dot{V}O_{2max}$  = maximal oxygen consumption;  $\dot{V}O_{2peak}$  = peak oxygen consumption

**2.6.1. In patients with lung cancer who are potential candidates for curative surgical resection, it is recommended that they be assessed by a multidisciplinary team, which includes a thoracic surgeon specializing in lung cancer, medical oncologist, radiation oncologist and pulmonologist (Grade 1C).**

**2.6.2. In elderly patients with lung cancer who are potential candidates for curative surgical resection it is recommended that they be fully evaluated regardless of age (Grade 1C).**

**2.6.3. In patients with lung cancer being considered for surgery who have increased perioperative cardiovascular risk, a preoperative cardiologic evaluation is recommended, with further management according to existing cardiologic guidelines for non cardiac surgery (Grade 1C).**

**3.1.1.1. In patients with lung cancer being considered for surgery, it is recommended that both FEV<sub>1</sub> and diffusing capacity for carbon monoxide (DLCO) be measured in all patients and that both predicted postoperative (PPO) FEV<sub>1</sub> and PPO DLCO are calculated (Grade 1B).**

Manuscript received September 24, 2012; revision accepted November 30, 2012.

**Affiliations:** From the Division of Thoracic Surgery (Dr Brunelli), Ospedale Riuniti, Ancona, Italy; the Section of Thoracic Surgery (Dr Kim), Yale University School of Medicine, New Haven, CT; the Department of Medicine (Dr Berger); and the Division of Pulmonary, Critical Care Medicine and Sleep Medicine (Dr Addrizzo-Harris), New York University School of Medicine, New York, NY.

**Funding/Sponsors:** The overall process for the development of these guidelines, including matters pertaining to funding and conflicts of interest, are described in the methodology article.<sup>1</sup> The development of this guideline was supported primarily by the American College of Chest Physicians. The lung cancer guidelines conference was supported in part by a grant from the Lung Cancer Research Foundation. The publication and dissemination of the guidelines was supported in part by a 2009 independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. COI grids reflecting the conflicts of interest that were current as of the date of the conference and voting are posted in the online supplementary materials.

**Disclaimer:** American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at <http://dx.doi.org/10.1378/chest.143551>.

**Correspondence to:** Doreen J. Addrizzo-Harris, MD, FCCP, Tisch Hospital, Division of Pulmonary, Critical Care Medicine and Sleep Medicine, New York University School of Medicine, 550 First Ave, New York, NY 10016; e-mail: [Doreen.addrizzo@nyumc.org](mailto:Doreen.addrizzo@nyumc.org)

© 2013 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1378/chest.12-2395

**3.2.1.1. In patients with lung cancer being considered for surgery, if both PPO FEV<sub>1</sub> and PPO DLCO are > 60% predicted, no further tests are recommended (Grade 1C).**

*Remark:* Values of both PPO FEV<sub>1</sub> and PPO DLCO > 60% indicate low risk for perioperative death and cardiopulmonary complications following resection including pneumonectomy.

**3.2.1.2. In patients with lung cancer being considered for surgery, if either the PPO FEV<sub>1</sub> or PPO DLCO are < 60% predicted and both are above 30% predicted, it is recommended that a low technology exercise test (stair climb or shuttle walk test [SWT]) is performed (Grade 1C).**

**3.2.1.3. In patients with lung cancer being considered for surgery, with either a PPO FEV<sub>1</sub> < 30% predicted or a PPO DLCO < 30% predicted performance of a formal cardiopulmonary exercise test (CPET) with measurement of maximal oxygen consumption ( $\dot{V}O_{2max}$ ) is recommended (Grade 1B).**

*Remark:* Either a PPO FEV<sub>1</sub> < 30% predicted or a PPO DLCO < 30% predicted indicate an increased risk for perioperative death and cardiopulmonary complications with anatomic lung resection.

**3.9.1. In patients with lung cancer being considered for surgery who walk < 25 shuttles (or < 400 m) on the SWT or climb < 22 m at symptom limited stair climbing test, performance of a formal CPET with measurement of  $\dot{V}O_{2max}$  is recommended (Grade 1C).**

*Remark:* Walking < 25 shuttles (or < 400 m) on the SWT or climbing < 22 m at symptom limited stair climbing test suggests an increased risk for perioperative death and cardiopulmonary complications with anatomic lung resection.

**3.9.2. In patients with lung cancer being considered for surgery and a  $\dot{V}O_{2max}$  < 10 mL/kg/min or < 35% predicted it is recommended that they are counseled about minimally invasive surgery, sublobar resections or nonoperative treatment options for their lung cancer (Grade 1C).**

*Remark:* a  $\dot{V}O_{2max}$  < 10 mL/kg/min or < 35% predicted indicates a high risk for perioperative death and cardiopulmonary complications with major anatomic lung resection through thoracotomy.

*Remark:* For values of  $\dot{V}O_{2max}$  in the range of 10 to 15 mL/kg/min an increased risk of mortality is expected. However, data are less definitive for making

decisions based solely on those values without taking into account other factors like PPO FEV<sub>1</sub> and DLCO as well as patient comorbidities.

**6.1.1. In patients with lung cancer being considered for surgery who undergo neoadjuvant therapy, it is suggested that repeat pulmonary function testing with diffusion capacity be performed after completion of neoadjuvant therapy (Grade 2C).**

**7.4.1. In patients with lung cancer in an area of upper lobe emphysema who are candidates for lung volume reduction surgery (LVRS), combined LVRS and lung cancer resection is suggested (Grade 2C).**

**7.4.2. In all patients with lung cancer being considered for surgery who are actively smoking, tobacco dependence treatment is recommended (Grade 1C).**

*Remark:* Smoking cessation is associated with short-term perioperative and long-term survival benefits (see also specific recommendations in chapter 6, 3.1.1, 3.1.2, 3.1.3).

**7.4.3. In patients with lung cancer being considered for surgery and deemed at high risk (as defined by the proposed functional algorithm, ie, PPO FEV<sub>1</sub> or PPO DLCO < 60% and  $\dot{V}_{O_2\max}$  < 10 mL/kg/min or < 35%), preoperative or postoperative pulmonary rehabilitation is recommended (Grade 1C).**

Surgery is the best option for cure in patients with early-stage non-small cell lung cancer, but many potentially resectable tumors occur, usually due to cigarette smoking, in individuals with abnormal pulmonary function. These patients may be at increased risk of both immediate perioperative complications and long-term disability following curative-intent surgical resection of their lung cancer. Cigarette smoking also predisposes these patients to other comorbid conditions, specifically atherosclerotic cardiovascular disease, which further increases perioperative risk. Consequently, in considering whether a patient should undergo curative-intent surgical resection of lung cancer, the possible short-term perioperative risk from comorbid cardiopulmonary disease and the long-term risk of pulmonary disability must be balanced against the possible risk of reduced survival if an oncologically suboptimal treatment strategy is chosen.

The task of the preoperative physiologic assessment is to identify patients at increased risk of both perioperative complications and long-term disability

from lung cancer resection surgery using the least invasive tests possible, and to assess the magnitude of that risk. This assessment allows the patient to be counseled regarding treatment options and risks, so that an informed decision can be made. Identification of patients at an elevated risk by the preoperative physiologic assessment also provides a basis for developing interventions to reduce the risk of perioperative complications and long-term pulmonary disability from curative-intent surgical resection of lung cancer.

## 1.0 METHODS

The goal of this article is to update previous recommendations on the preoperative physiologic evaluation of patients with lung cancer being considered for curative-intent surgery.<sup>2,3</sup> A formal process was followed. The topic editor and writing committee drafted evidence questions using a population, intervention, comparator or control group, outcome (PICO) format whenever possible. These PICO questions can be accessed in the online supplementary materials for each article where they were developed. Outcomes were restricted to those that are patient important, not simply research focused. Searches occurred for relevant clinical evidence, mostly in the form of original research or systematic reviews. Original research included all levels of evidence (randomized controlled trials as well as observational studies), as long as they appeared in peer-reviewed publications, which was the minimal threshold.

The PICO questions then informed the search strategies, which are available upon request. The writing committee conducted their literature searches in PubMed, Google Scholar, and Scopus. Searches were not limited by publication date; however, most covered the period 2005 to the present. The references in the second edition of the American College of Chest Physicians (ACCP) Lung Cancer Guidelines were used for the majority of articles written before 2005.

Recommendations were developed by the writing committee, graded by a standardized method (see the article by Lewis et al,<sup>1</sup> "Methodology for Guidelines for Lung Cancer," in the ACCP Lung Cancer Guidelines), and were reviewed by all members of the Lung Cancer Panel and the Thoracic Oncology Network prior to approval by the Guidelines Oversight Committee and the Board of Regents of the ACCP.

Although numerous reviews have been published on the preoperative risk assessment of patients with lung cancer being considered for curative-intent surgical resection,<sup>4-9</sup> most available guidelines on the management of non-small cell lung cancer do not address the preoperative evaluation process.<sup>10-16</sup> The British Thoracic Society,<sup>17</sup> the ACCP,<sup>3</sup> and the European Respiratory Society (ERS) jointly with the European Society of Thoracic Surgeons (ESTS)<sup>15</sup> have provided two guidelines with specific recommendations on the steps needed to evaluate preoperative risk. The recommendations of these guidelines follow a similar approach, relying on physiologic testing to estimate perioperative risk and the effect of resection on postoperative lung function.

## 2.0 GENERAL ISSUES REGARDING RISK

### 2.1 Multidisciplinary Team

Patients with lung cancer who are seen by a physician with expertise in the management of this disease



are more likely to have histologic confirmation of lung cancer and referral for potentially curative treatment.<sup>19,20</sup> Evaluation by a multidisciplinary team, which includes a thoracic surgeon specializing in lung cancer, a medical oncologist, a radiation oncologist, and a pulmonologist, as is the practice now in many countries, is important in the assessment of risk and benefit of curative-intent surgery. Multidisciplinary input is especially useful in patients who are marginal surgical candidates as a basis for discussing the proposed surgical procedure and treatment options with the patient and appropriate family or surrogates.

Two of the eight comparative studies included in a systematic review<sup>21</sup> reported an improvement in survival in patients evaluated by a multidisciplinary team (in inoperable patients and in elderly patients, respectively).<sup>22,23</sup> Although the other studies did not find a difference in survival, three reported increased resection rates<sup>24,25</sup> and two reported increased rates of receiving chemotherapy or radiotherapy.<sup>22,23</sup> Similar findings were noted in the two most recent observational reports, which showed that multidisciplinary team evaluation was associated with improved practice patterns (ie, pathologic diagnosis, receipt of chemotherapy or radiotherapy, complete staging, adherence to guidelines, and shorter interval from diagnosis to treatment).<sup>26,27</sup>

## 2.2 Risk Thresholds

In presenting the option of curative-intent surgical therapy to a patient with lung cancer, it is important to recognize that risk assessment is a complex process. Risks related to standard surgical resection for lung cancer (lobectomy or greater removal of lung tissue) include perioperative morbidity and mortality and long-term functional disability. Individual patient circumstances increase or decrease the risks of standard surgical resection. In this guideline, the effect on perioperative mortality, morbidity, residual functional status, and quality of life with curative lung cancer resection for various physiologic abnormalities is extrapolated from published data. However, patient preference as to the maximal acceptable surgical risk (eg, the threshold mortality rate above which the patient would not accept the procedure) should also be explored. Mathematical approaches, based on decision analysis techniques, have been useful for conceptually describing the interplay between risk and patient preference, but are not routinely used for individual patient care.<sup>28</sup> The use of minimally invasive thoracic surgery and sublobar anatomic resections (segmentectomy), whenever technically and oncologically feasible, needs to be taken into account when discussing the risk of surgery with the patient. In fact, both these techniques have been shown to

substantially reduce the perioperative risk and the physiologic impact and to provide comparable or even superior oncologic results. The responsible physician should also keep in mind and discuss nonsurgical treatment alternatives, such as conventional radiotherapy, stereotactic radiotherapy, and radiofrequency ablation, if the risk of surgery is deemed unacceptably high by both surgeon and patient.

## 2.3 Age

The prevalence of lung cancer increases with age. In North America it has been estimated that the prevalence of lung cancer increases from 14 per 100,000 population at age 40 years to 477 per 100,000 population at age 70 years for men. For women, it increases from 16 per 100,000 population at age 40 to 342 per 100,000 population at age 70 years. Approximately 30% to 35% of candidates for lung resection for lung cancer are > 70 years of age, as reported in the most recent Society of Thoracic Surgeons (STS) and ESTS general thoracic surgery databases. Although age has been traditionally considered a risk factor, the most recent guidelines have emphasized that age alone is not a contraindication to surgery.<sup>3,18</sup> The increased surgical risk, which may be observed in elderly patients, is probably a function of the underlying comorbidities. In this regard, the ERS-ESTS guidelines have recommended that the cardiopulmonary fitness of elderly patients with lung cancer be fully evaluated without any prejudice regarding age.<sup>18</sup> A similar recommendation has been proposed by the European Organization for Research and Treatment of Cancer elderly task force and the Lung Cancer Group, and by the International Society for Geriatric Oncology in a joint expert opinion paper.<sup>29</sup> They advised that surgery in the early stages of disease not be dismissed based solely on chronologic age.

Factors such as tumor stage, patient life expectancy, performance status, and presence of underlying comorbidities should be taken into account in the surgical decision-making process. Careful patient selection with preoperative evaluation is mandatory, however, and could significantly improve the results. Evidence<sup>30-40</sup> has shown that for patients > 80 years old, reported average mortality is between 0% and 9%; however, it should be kept in mind that in most series the most frequent operation was lobectomy or sublobar resections. Very elderly patients have reduced resection rates<sup>40-42</sup> and are more frequently submitted to sublobar resections rather than lobectomy. Relative long-term survival of very elderly patients appears to be comparable to younger ones in some studies,<sup>34,40,42</sup> but not in others in which survival in patients > 80 was shorter than in younger patients.<sup>41,43,44</sup> In general, reported 5-year survival in

stage I after pulmonary resection varies between 50% and 60%.<sup>35,36,38,41,42,45-47</sup>

## 2.4 Cardiovascular Risk

Patients with lung cancer are predisposed to atherosclerotic cardiovascular disease because of cigarette smoking, and the prevalence of underlying coronary artery disease is about 11% to 17%.<sup>48,49</sup> The risk of major postoperative cardiac complications, including myocardial ischemia, pulmonary edema, ventricular fibrillation or primary cardiac arrest, complete heart block, and cardiac-related death,<sup>50</sup> is about 2% to 3% after lung resection.<sup>48,49</sup> As a consequence, a preoperative cardiovascular risk assessment should be performed. Guidelines have recommended the use of cardiac risk scores as a screening tool to select patients needing specialized preoperative cardiologic testing before proceeding to their surgical procedure. The American Heart Association/American College of Cardiology<sup>51</sup> and the European Society of Cardiology/European Society of Anesthesiology guidelines<sup>52</sup> recommend the revised cardiac risk index (RCRI)<sup>50</sup> as the preferred risk scoring tool to assess cardiac risk in patients undergoing noncardiac surgical procedures. Similarly, the joint ERS/ESTS task force on fitness for radical treatment of patients with lung cancer<sup>18</sup> endorsed these recommendations and proposed a cardiologic algorithm incorporating this scoring system as a preliminary screening instrument.

However, the RCRI was originally derived from a mixed surgical population including only a minority of patients undergoing thoracic surgery. For this reason, this scoring system was recalibrated in a lung resection population,<sup>48</sup> and the recalibrated score (defined as thoracic RCRI [ThRCRI]) was then validated in external populations showing a good discrimination ability.<sup>48,53</sup> When using the cardiologic algorithm as a preliminary step in the functional workup of the lung resection candidate, it seems advisable to replace the traditional RCRI with the more specific and recently revised ThRCRI (Fig 1).

In summary, patients with ThRCRI > 1.5 or any cardiac condition requiring medication or a newly suspected cardiac condition or limited exercise tolerance (inability to climb two flights of stairs) should be referred for a cardiac consultation. Noninvasive testing and treatments as per American Heart Association/American College of Cardiology guidelines<sup>51,54</sup> should be indicated in these patients (Fig 1).

On the other hand, aggressive cardiac interventions should be reserved only for patients who need them irrespective of surgery, but interventions specifically for surgery are of limited benefit. For example, prophylactic coronary revascularization has not been demonstrated to reduce risk.<sup>55,56</sup> Furthermore, the

need for aggressive antiplatelet therapy, which is recommended for approximately 6 weeks after coronary angioplasty and/or a bare metal stent and for > 1 year after a drug-eluting stent, may represent a major surgical challenge,<sup>57</sup> although evidence has shown that patients who are receiving clopidogrel and who have a coronary artery stent placed can safely undergo general thoracic surgery without increased risk of bleeding and with a reduced risk of perioperative myocardial infarction compared with control subjects undergoing surgery without antiplatelet therapy.<sup>58</sup>


$\beta$ -Blockers are commonly used to reduce perioperative myocardial infarction.<sup>59,60</sup> However, a randomized trial has shown that commonly used  $\beta$ -blocker regimens increase the risk of stroke, presumably because of bradycardia and hypotension, and can increase overall mortality.<sup>61</sup> Therefore, we do not recommend starting a new perioperative  $\beta$ -blockade in patients with ischemic heart disease, but favor continuation of  $\beta$ -blockers in patients already taking them.  $\beta$ -blockers may be beneficial as new therapy only in very high-risk patients, in whom their cardioprotective benefits may outweigh their bradycardic and hypotensive effects.<sup>62</sup>

Cardiopulmonary exercise testing (CPET) has been proposed as a useful tool for detecting both overt and occult exercise-induced myocardial ischemia, with a diagnostic accuracy similar to that of a single-photon emission computed tomographic myocardial perfusion study<sup>63-65</sup> and superior to standard ECG stress testing.<sup>66</sup> Several variables obtained during CPET, including oxygen consumption relative to heart rate and work rate, provide consistent, quantitative patterns of abnormal physiologic responses to graded exercise when left ventricular dysfunction is caused by myocardial ischemia. For this reason, CPET can be proposed as a noninvasive test to detect and quantify myocardial perfusion defects in patients at increased risk of coronary artery disease. In fact, in addition to providing information on the presence and severity of myocardial ischemia, it will provide data on peak oxygen consumption ( $\dot{V}O_{2peak}$ ), a parameter that has been associated with postoperative outcome (see paragraph on CPET). We therefore recommend referral of patients with a positive cardiac history and increased cardiac risk for a CPET to better define the coronary reserve and cardiac function (Fig 1).

## 2.5 Surgical Experience

European guidelines on fitness for radical treatment<sup>18</sup> have recommended that the surgical treatment of patients with lung cancer be performed in specialized centers by qualified thoracic surgeons, because specialization has been shown to have a positive impact on resectability, postoperative mortality,

FIGURE 1. [Sections 2.4, 3.0, 4.0] Physiologic evaluation cardiac algorithm. \*ThRCRI.<sup>48</sup> Pneumonec-  
tomy: 1.5 points; previous ischemic heart disease: 1.5 points; previous stroke or transient ischemic  
attack: 1.5 points; creatinine > 2 mg/dL: 1 point. ACC = American College of Cardiology; AHA = American  
Heart Association; CABG = coronary artery bypass graft surgery; CPET = cardiopulmonary exercise test;  
PCI = percutaneous coronary intervention. Modified and reproduced with permission of the European  
Respiratory Society. *Eur Respir J*. July 2009 34:17-41. doi:10.1183/09031936.00184308



\*ThRCRI (Thoracic revised Cardiac Risk Index). Ref 50

- Pneumonectomy: 1.5 points
- Previous ischemic heart disease: 1.5 points
- Previous stroke or TIA: 1.5 points
- Creatinine > 2mg/dl : 1 point

and long-term survival. In fact, with the exception of one report,<sup>67</sup> most authors found reduced mortality rates (crude or adjusted for concomitant risk factors) when patients with lung cancer were operated

on by board-certified, specialized thoracic surgeons, compared with general surgeons.<sup>68-71</sup> Some authors reported, in addition to reduced operative mortality, a longer survival<sup>71</sup> and increased resection rates<sup>67</sup> in

patients with lung cancer managed in hospitals with specialized thoracic surgeons.

Many studies on the association between hospital procedural volume and outcome have been published. Most of the studies reported a favorable influence of high surgical volume on operative mortality<sup>72-80</sup>; however, this association was not confirmed by others.<sup>81-85</sup> Other studies found a better long-term survival associated with high-volume hospitals or surgeons.<sup>74,78,80,86-88</sup> Some studies have shown that surgeon's volume was more strongly associated with mortality than was hospital volume,<sup>89</sup> but others did not confirm this result<sup>76,77</sup> and found that hospital volume, rather than individual surgeon volume, was more linked to outcome. For lung resection, surgeon volume was found to be strongly correlated with hospital volume (ie, high-volume surgeons tend to operate in high-volume hospitals).<sup>76,77</sup> Given the variable volume thresholds that have been used in the literature (ie, the definition of high volume ranges from 20 to > 90 cases/y), it is difficult to identify a minimal surgical volume for individual surgeons or centers. Based on the data from the literature and a consensus opinion of experts, the ERS-ESTS guidelines advised that lung resections be performed in centers with a minimal surgical volume of 20 to 25 major anatomic resections per year.<sup>18</sup>

## 2.6 Recommendations

**2.6.1. In patients with lung cancer who are potential candidates for curative surgical resection, it is recommended that they be assessed by a multidisciplinary team, which includes a thoracic surgeon specializing in lung cancer, medical oncologist, radiation oncologist and pulmonologist (Grade 1C).**

**2.6.2. In elderly patients with lung cancer who are potential candidates for curative surgical resection it is recommended that they be fully evaluated regardless of age (Grade 1C).**

**2.6.3. In patients with lung cancer being considered for surgery who have increased perioperative cardiovascular risk, a preoperative cardiologic evaluation is recommended, with further management according to existing cardiologic guidelines for non cardiac surgery (Grade 1C).**

## 3.0 RISK OF PERIOPERATIVE MORBIDITY AND MORTALITY

Morbidity and mortality rates following lung resection have decreased over time.<sup>79,90</sup> Current rates of

mortality reported in the STS or ESTS general thoracic surgery databases are around 1.6% to 2.3% after lobectomy and 3.7% to 6.7% after pneumonectomy. These numbers are somewhat lower than reported previously.<sup>79</sup> Newer or refined surgical techniques, such as the use of muscle-sparing and intercostal nerve-sparing thoracotomy,<sup>91</sup> video-assisted thoracoscopy,<sup>92,93</sup> and robotically assisted lung resection,<sup>94</sup> have certainly contributed to minimizing the postoperative risks of morbidity and reductions in lung function. For instance, a propensity-score case-matched analysis based on the data present in the STS general thoracic surgery database has shown a significantly lower incidence of complications and a shorter length of stay (4 days vs 6 days,  $P < .0001$ ) compared with open lobectomy.<sup>92</sup> However, even with modern anesthetic, surgical, and postoperative care techniques, the risk of perioperative morbidity and mortality following either lobectomy or pneumonectomy is still appreciable. The approach to estimating these risks from underlying cardiopulmonary disease is based on a preoperative physiologic assessment (see Fig 1).

### 3.1 Spirometry and Diffusing Capacity

Spirometry, and in particular that of FEV<sub>1</sub> and predicted postoperative (PPO) FEV<sub>1</sub>, has traditionally represented the key test in the functional workup of surgical candidates with lung cancer. A reduced FEV<sub>1</sub> or PPO FEV<sub>1</sub> has been associated with increased respiratory morbidity and mortality rates.<sup>95-101</sup> Berry et al<sup>95</sup> showed that FEV<sub>1</sub> was an independent predictor of respiratory complications. Patients with a preoperative FEV<sub>1</sub> < 30% had an incidence of respiratory morbidity as high as 43%, whereas those with an FEV<sub>1</sub> > 60% had a morbidity rate of 12%. Ferguson et al<sup>97</sup> used classification and regression tree analysis and found that FEV<sub>1</sub> was an independent predictor of pulmonary morbidity (OR, 1.1 for every 10% decrease in FEV<sub>1</sub>) and cardiovascular complications (OR, 1.13 for every 10% decrease in FEV<sub>1</sub>). By using receiver-operating characteristic analysis, Licker et al<sup>99</sup> confirmed that the best cutoff value of FEV<sub>1</sub> for predicting respiratory complications was 60%.

Despite these findings, guidelines<sup>18</sup> have questioned their pivotal roles in selecting patients for operation. This conclusion was based on a series of studies showing a limited role of these parameters in predicting complications in patients with COPD,<sup>102,103</sup> likely due to the so-called "lobar volume reduction effect." In patients with lung cancer and moderate to severe COPD, the resection of the most affected parenchyma may determine an improvement in respiratory mechanics and elastic recoil. Several studies have shown a minimal loss or even an improvement



in respiratory function 3 to 6 months after lobectomy in these patients.<sup>104-111</sup> A most important finding is that the lobar volume reduction effect takes place immediately after surgery,<sup>112</sup> demonstrating that the impact of operation in patients with COPD is lower than expected in patients without COPD.

Interest in the diffusing capacity for carbon monoxide (DLCO) as a useful marker of operative risk was stimulated by Ferguson et al,<sup>113</sup> who related preoperative DLCO to postresection morbidity and mortality in 237 patients. Patients were selected for surgery on the basis of clinical evaluation and spirometry, but not on the DLCO, which was also measured. They found the preoperative uncorrected DLCO expressed as percent predicted to have a higher correlation with postoperative deaths than the FEV<sub>1</sub> expressed as percent predicted, or any other factor tested. In this study, a DLCO < 60% predicted was associated with a 25% mortality and a 40% pulmonary morbidity. This finding was subsequently confirmed by other authors.<sup>95,97,114-116</sup> Similar to PPO FEV<sub>1</sub>, a reduced PPO DLCO has been shown to be strongly associated with the risk of pulmonary complications and mortality following lung resection.<sup>117,118</sup>

Previous guidelines have recommended measuring DLCO in patients with evidence of diffuse parenchymal lung disease on radiographic studies, dyspnea on exertion, or a reduced FEV<sub>1</sub>. However, some contributions have shown that the correlation between FEV<sub>1</sub> and DLCO is consistently poor<sup>119,120</sup> and that a reduced PPO DLCO is a predictor of cardiopulmonary complications and mortality even in patients with an otherwise normal FEV<sub>1</sub>.<sup>119,120</sup> More than 40% of patients with an FEV<sub>1</sub> > 80% may have a DLCO < 80%, and 7% of them may have a PPO DLCO < 40%.<sup>119</sup> As a consequence, guidelines have recommended the systematic measurement of DLCO in lung resection candidates regardless of the FEV<sub>1</sub> value.<sup>18</sup>

In addition to postoperative morbidity and mortality, the value of DLCO has been associated with long-term survival<sup>121,122</sup> and residual quality of life.<sup>123</sup> Liptay et al<sup>121</sup> showed that a DLCO < 40% was associated with an increased risk of late death due to causes other than cancer. Ferguson et al<sup>122</sup> showed that a DLCO value < 60% had a hazard ratio of 1.35 for death.

Therefore, we recommend systematically measuring DLCO in all lung resection candidates regardless of their preoperative level of FEV<sub>1</sub> because at least 40% of them can have an abnormal DLCO despite a normal FEV<sub>1</sub> and PPO DLCO has been shown to be a valid predictor of major morbidity even in patients without airflow limitation. Most of the studies analyzing the role of DLCO in risk stratification took into consideration the uncorrected measurement of DLCO. Any form of correction/adjustment

(ie, hemoglobin concentration or alveolar ventilation) should be reported in future analysis. DLCO measurement should be performed according to the joint ERS/American Thoracic Society clinical practice guidelines.<sup>124</sup>

### 3.1.1 Recommendation

**3.1.1.1. In patients with lung cancer being considered for surgery, it is recommended that both FEV<sub>1</sub> and DLCO be measured in all patients and that both PPO FEV<sub>1</sub> and PPO DLCO are calculated (Grade 1B).**

## 3.2 PPO Lung Function

Several criteria should be met before using assessment of lung function to predict postoperative clinical outcomes. First, the quality of the patient performance and test reproducibility must be optimal and should conform to standards.<sup>124,125</sup> Once performance is adequate, specific attention must be directed to understanding the cause of abnormal results. For example, reduction in FEV<sub>1</sub> due to weakness may be associated with a different surgical outcome as compared with a patient with COPD, despite identical airflow. In addition, the presence of an obstructing endobronchial lesion may produce abnormalities on baseline testing that can be expected to improve postoperatively. Unfortunately, there are limited data that address these and other similar issues and, therefore, the remainder of this section is specifically targeted to the assessment of subjects with underlying COPD.

The risk of operative complications has been linked to PPO lung function. Separate formulas are used to estimate the PPO lung function for patients undergoing pneumonectomy vs lobectomy. The PPO values can be converted into percent predicted using standard equations. For illustrative purposes, the formulas below are used for estimation of PPO FEV<sub>1</sub>; the same equations can be used to estimate the PPO DLCO.

Pneumonectomy: the perfusion method is used with the following formula:

$$\text{PPO FEV}_1 = \text{preoperative FEV}_1 \times (1 - \text{fraction of total perfusion for the resected lung})$$

The preoperative FEV<sub>1</sub> is taken as the best measured postbronchodilator value. A quantitative radionuclide perfusion scan is performed to measure the fraction of total perfusion for the resected lung. Standards for perfusion scan have been published by the American College of Radiology (available at [http://www.acr.org/~media/ACR/Documents/PGTS/guidelines/Pulmonary\\_Scintigraphy.pdf](http://www.acr.org/~media/ACR/Documents/PGTS/guidelines/Pulmonary_Scintigraphy.pdf))



Lobectomy: the anatomic method is used with the following formula:

$$\text{PPO FEV}_1 = \text{preoperative FEV}_1 \times (1 - y/z)$$

The preoperative  $\text{FEV}_1$  is taken as the best measured postbronchodilator value. The number of functional or unobstructed lung segments to be removed is  $y$  and the total number of functional segments is  $z$ .<sup>126</sup> The total number of segments for both lungs is 19 (10 in the right lung [three in the upper, two in the middle, five in the lower] and nine in the left lung [five in the upper and four in the lower]).

In a study of >1,400 subjects undergoing lung resection, Alam et al<sup>127</sup> demonstrated that the OR for development of postoperative respiratory complications increases as the PPO  $\text{FEV}_1$  and PPO DLCO fall (a 10% increase in the risk of complications for every 5% decrement in PPO lung function). Accordingly, previous guidelines have recommended estimation of PPO pulmonary function for all patients with an abnormal  $\text{FEV}_1$  (<80% predicted) who are being considered for surgical resection.<sup>3</sup> Historically, the operative risk has been considered acceptable for subjects with a PPO  $\text{FEV}_1$  and PPO DLCO >40% predicted. For patients who do not meet these criteria, recommendations included either assessment of exercise capacity as an additional preoperative risk-stratification method or consideration for alternate and/or limited therapies.

However, although many data established a PPO  $\text{FEV}_1$  of >40% as a criterion for patients who are likely to do well, exactly how patients below this threshold will fare is less well established. Multiple observations suggest that patients who do not meet these criteria may still undergo surgery with an acceptable clinical outcome in series that include sublobar resections. Several studies have demonstrated that low values for morbidity (about 15%-25%) and mortality (about 1%-15%) can be obtained, even in subjects with severe reduction in airflow; mean preoperative  $\text{FEV}_1$  in these studies ranges from 26% to 45% predicted.<sup>103,128,129</sup> Note that these values for preoperative  $\text{FEV}_1$  were frequently below the threshold recommended for postoperative lung function, highlighting that surgery can be performed safely in selected patients with markedly abnormal lung function at baseline. The surgical techniques used in these studies varied and included limited wedge or segment resections, a combination of resection with lung volume reduction, and both open and video-assisted thoracoscopic approaches.

Long-term survival has been analyzed in subjects with severe airflow limitation undergoing surgical resection of lung tumors. Martin-Ucar et al<sup>128</sup> evaluated 5-year survival in patients with upper-lobe stage I

disease. In subjects with severe underlying COPD and a PPO  $\text{FEV}_1$  <40% (mean, 34%) predicted, the survival rate was 35% after lobectomy. Although this was lower than the 65% survival observed in a comparison group with superior lung function (PPO  $\text{FEV}_1$  >40; mean, 61%), the survival was still better than expected if resection had not been performed.<sup>128</sup> In addition, Lau et al<sup>129</sup> reported favorable results in patients with severe COPD when resection was performed using video-assisted thoracic surgery (VATS). In this study, improvements were also noted in both hospital mortality (8% vs 14%) and long-term survival (5-year survival, 48% vs 18%) with VATS compared with thoracotomy.

The favorable clinical outcomes obtained in some patients with markedly abnormal lung function have multiple potential explanations. Improvements in surgical technique and introduction of VATS may be associated with beneficial postoperative results. Endoh et al<sup>130</sup> have demonstrated that postoperative fall in lung function is lower in subjects undergoing VATS compared with subjects treated with an open surgical approach. Similarly, improvement in perioperative management and tailoring of therapy to individual patients may produce benefits in clinical outcome. An additional benefit may be obtained by performing limited resections. In a study by Linden et al,<sup>103</sup> analysis of frozen sections at time of surgery allowed for wedge resections in 65% of subjects. Although limited resection resulted in a favorable short-term outcome, these benefits should be considered after consideration of the risk of local recurrence. Lastly, lung resection is associated with a "lung volume reduction" effect.<sup>105,131-134</sup> Patients with underlying COPD may demonstrate a smaller reduction in  $\text{FEV}_1$  postoperatively than do subjects with normal spirometry.<sup>130,131,135</sup> In addition, an inverse relationship between postoperative decline in  $\text{FEV}_1$  and baseline severity of airflow obstruction has been demonstrated.<sup>132-134</sup> Lastly, patients with COPD may demonstrate improvement in postoperative  $\text{FEV}_1$ , despite lung resection.<sup>105,110,134</sup>

Some advances may improve the ability of PPO lung function to predict postoperative complications. Several studies have evaluated the use of PPO DLCO specifically in patients with a normal  $\text{FEV}_1$  at baseline.<sup>115,119,120</sup> The rationale for these studies is based on the different components of respiratory function assessed by these tests (lung mechanics assessed by spirometry vs gas exchange assessed by diffusion) and the poor correlation observed between  $\text{FEV}_1$  and DLCO.<sup>119,120</sup> These studies identified that assessment of diffusion capacity and calculation of PPO DLCO were predictive of postoperative morbidity and respiratory complications, even in the presence of normal airflow. No relationship was demonstrable between mortality and PPO DLCO.

Because current equations to predict postoperative lung function are only valid 1 to 3 months after surgery,<sup>111</sup> attention has focused on the change in lung function observed in the immediate postoperative period. Varela et al<sup>136</sup> demonstrated that the best predictor of surgical morbidity and mortality was the measured FEV<sub>1</sub> on postoperative day 1 rather than the PPO FEV<sub>1</sub>. These results were extended by studies that focused on the evolution of lung function during the immediate postoperative period, when respiratory complications occur. Data demonstrate that lung function during this period is markedly lower than the corresponding PPO values.<sup>111,133,135,136</sup> On postoperative day 1, the FEV<sub>1</sub> was only 71% of the PPO value.<sup>135</sup> The FEV<sub>1</sub> progressively increased through the first week and on day 7 the FEV<sub>1</sub> reached 93% of the PPO value.<sup>135</sup> Based on these results, Brunelli et al<sup>112,137</sup> published methods to estimate the FEV<sub>1</sub> on the first postoperative day and at hospital discharge. Although the estimated values closely matched the observed data, several limitations of these studies affect their applicability at present. These studies evaluated only patients who passed a rigorous screening assessment to determine operative risk, and the relationship to clinical outcomes was not analyzed. Despite these considerations, these studies do highlight the limitations associated with current predictive models.

The considerations mentioned suggest that the existing algorithms for preoperative pulmonary assessment can be extended to offer potentially curative surgery to patients with more severe abnormalities in lung function at baseline. Several studies have demonstrated acceptable postoperative outcome in patients with a PPO lung function as low as 30% predicted. Puente-Maestú et al<sup>138</sup> compared acute morbidity and mortality, as well as 2-year survival, in subjects with a PPO FEV<sub>1</sub> and PPO DLCO >30% predicted. In this study, preoperative evaluation included estimates of PPO oxygen consumption ( $\dot{V}O_2$ ) during exercise, in addition to estimates of PPO FEV<sub>1</sub> and DLCO. Surgery was performed in subjects with PPO lung function <40% predicted provided that the estimated PPO oxygen consumption during exercise exceeded 10 mL/kg/min. The operative mortality was 6% despite the inclusion of subjects with severe lung function abnormalities.

In addition, the data demonstrated improved 2-year survival in subjects treated with surgical resection (66%) compared with subjects who either refused surgery or were deemed unfit for surgery (19%). Of importance, although survival was lower in subjects with the most abnormal PPO lung function (between 30% and 40% predicted) compared with healthier subjects (survival = 57% vs 71%), the difference was not statistically significant and far exceeded

the expected and observed survival in subjects who did not undergo surgery. Although the results of this study are encouraging, applicability to all clinical centers would be limited based on availability of CPET.

As an alternate approach, several groups have used lower technology tests, such as the stair-climbing test.<sup>112,133,136,137,139</sup> Patients who were able to climb >12 m during the stair-climbing test were offered surgery. Operative morbidity and mortality using this cutoff value during the stair-climbing test were comparable to data obtained with full CPET. Taken together, these studies suggest that curative lung resection surgery can be performed in patients with PPO lung function as low as 30% predicted, provided the patient demonstrates an acceptable exercise capacity.

### 3.2.1 Recommendations

**3.2.1.1. In patients with lung cancer being considered for surgery, if both PPO FEV<sub>1</sub> and PPO DLCO are >60% predicted, no further tests are recommended (Grade 1C).**

*Remark:* Values of both PPO FEV<sub>1</sub> and PPO DLCO are >60% indicate low risk for perioperative death and cardiopulmonary complications following resection including pneumonectomy.

**3.2.1.2. In patients with lung cancer being considered for surgery, if either the PPO FEV<sub>1</sub> or PPO DLCO are <60% predicted and both are above 30% predicted, it is recommended that a low technology exercise test (stair climb or SWT) is performed (Grade 1C).**

**3.2.1.3. In patients with lung cancer being considered for surgery, with either a PPO FEV<sub>1</sub> <30% predicted or a PPO DLCO <30% predicted performance of a formal CPET with measurement of  $\dot{V}O_{2\max}$  is recommended (Grade 1B).**

*Remark:* Either a PPO FEV<sub>1</sub> <30% predicted or a PPO DLCO <30% predicted indicate an increased risk for perioperative death and cardiopulmonary complications with anatomic lung resection.

### 3.3 Cardiopulmonary Exercise Testing

Formal CPET is a sophisticated physiologic testing technique that includes recording the exercise electrocardiogram, heart rate response to exercise, minute ventilation, and oxygen uptake per minute. Maximal oxygen consumption ( $\dot{V}O_{2\max}$ ) is measured from this type of exercise test and has been recommended by previous guidelines<sup>3,17</sup> as the next step in the preoperative risk-assessment process in those patients with compromised pulmonary function.

European guidelines have emphasized the role of CPET in the preoperative functional workup.<sup>18</sup> CPET was recommended in every patient with either an FEV<sub>1</sub> or a DLCO < 80% predicted value. Patients with a  $\dot{V}O_2\text{max}$  > 20 mL/kg/min or 75% predicted can safely undergo the planned resection (up to pneumonectomy) without further testing. Only in those patients with a  $\dot{V}O_2\text{max}$  < 20 mL/kg/min should split lung functions (% PPO FEV<sub>1</sub> and % PPO DLCO) be taken into consideration for risk stratification. A  $\dot{V}O_2\text{max}$  value < 10 mL/kg/min or 35% predicted is generally regarded as a contraindication to major anatomic resections. Risk of postoperative mortality can generally be stratified by  $\dot{V}O_2\text{max}$ . In several case series, patients with a  $\dot{V}O_2\text{max}$  < 10 mL/kg/min had a very high risk of postoperative death.<sup>114,140-142</sup> However, this assumption is based on a total of only 27 patients in four studies with an overall mortality rate of 26%. A meta-analysis confirmed the role of  $\dot{V}O_2\text{max}$  in discriminating patients at risk of postoperative cardiopulmonary complications. Benzo and colleagues<sup>143</sup> included 955 patients from 14 studies reporting  $\dot{V}O_2\text{max}$  as mL/kg/min and found that those patients developing postoperative complications had a preoperative  $\dot{V}O_2\text{max}$  3 mL/kg/min lower than those who did not. The authors concluded that this finding supported the use of CPET in risk stratification before lung resection.

A study by Loewen and colleagues<sup>144</sup> represents the largest published series of lung resection candidates evaluated with CPET. Complicated patients had a significantly lower  $\dot{V}O_2\text{max}$  compared with non-complicated patients, and this finding confirmed previous investigations.<sup>37,144-148</sup> Most of the studies published so far generally agree that a value of  $\dot{V}O_2\text{max}$  between 10 and 15 mL/kg/min or between 35% and 75% predicted values indicates an increased risk of perioperative death compared with higher values of  $\dot{V}O_2\text{max}$ .<sup>114,141,142,149-153</sup> On the other hand, values > 20 mL/kg/min have been reported to be safe for any kind of resection, including pneumonectomy.<sup>141,149,154-159</sup>  $\dot{V}O_2\text{max}$  has been shown to be helpful in further evaluating the risk of complications in patients with borderline lung function. Morice et al,<sup>160</sup> for instance, reported that eight patients with a percent predicted postoperative (% PPO) FEV<sub>1</sub> < 33 and a  $\dot{V}O_2\text{max}$  > 15 mL/kg/min underwent lobectomy with no fatal complications.

Most recently, Brunelli and colleagues<sup>148</sup> published a series including 200 major anatomic lung resections with complete CPET evaluation before surgery. Patients with a  $\dot{V}O_2\text{max}$  > 20 mL/kg/min had no mortality and only a 7% morbidity rate. Importantly, a value of  $\dot{V}O_2\text{max}$  < 12 mL/kg/min was associated with a mortality rate of 13%. Bolliger and colleagues<sup>151</sup> were the first to demonstrate that  $\dot{V}O_2\text{max}$  expressed

as a percentage of predicted value had a better discriminatory ability than when expressed in absolute values. The probability of developing complications in patients with a  $\dot{V}O_2\text{max}$  > 75% predicted was only 10% vs a probability of 90% in those with  $\dot{V}O_2\text{max}$  < 40% predicted. As with PPO FEV<sub>1</sub> and PPO DLCO, a segmental estimation of  $\dot{V}O_2\text{max}$  has been proposed by Bolliger and colleagues.<sup>161</sup> They found that a value of  $\dot{V}O_2\text{max}$  PPO < 10 mL/kg/min (or 35% predicted) was the only parameter able to identify all three patients who died in a subgroup of 25 patients at increased risk of complications.

In addition to  $\dot{V}O_2\text{max}$ , CPET can provide several other direct and indirect measures that can add to the preoperative risk stratification. Several authors have published articles about such derived parameters (ie, efficiency slope, oxygen pulse, minute ventilation to CO<sub>2</sub> production ratio slope), which have turned out to be predictive of cardiac and pulmonary complications.<sup>146,162-164</sup> A more liberal use of CPET is warranted by its role in early detecting coronary artery disease,<sup>63-66</sup> the association between  $\dot{V}O_2\text{max}$  and postoperative complications, and the possibility to use additional ergometric parameters to refine the analysis of the oxygen transport system.

### 3.4 Pulmonary Artery Pressures and Diffusing Capacity

Measurements of pulmonary arterial pressure during exercise have not proven to be helpful in predicting which patients will develop perioperative complications.<sup>142,165,166</sup> Measuring the diffusion capacity during exercise might be a better predictor of perioperative risk than  $\dot{V}O_2\text{max}$ , but is a technically demanding technique and not readily available.<sup>167,168</sup>

### 3.5 Stair-Climbing and Walking Tests

Stair climbing has been used historically as a surrogate for CPET. Stair climbing is an economic and widely applicable form of exercise. It is simple and rapid and requires few personnel and little equipment. The stair-climbing test appears to be a more stressful form of exercise and involves a larger muscle mass than cycling, yielding greater values of  $\dot{V}O_2\text{max}$ .<sup>140,169,170</sup> The test is extremely motivating for the patients who are pushed to reach a visible objective represented by the next landing. This approach was found to correlate with lung function; climbing three flights indicates an FEV<sub>1</sub> > 1.7 L and five flights an FEV<sub>1</sub> > 2 L.<sup>171</sup>

Several groups have shown that the ability to climb more than 12-14 m of stairs, which is approximately three flights of stairs, effectively identifies patients at low risk of postoperative complications usually following lobectomy, even though these patients might



have had a % PPO FEV<sub>1</sub> or % PPO DLCO < 40.<sup>172,173</sup> Brunelli and colleagues<sup>172</sup> reported their preliminary experience in 160 lung resection candidates. The altitude reached during a preoperative stair-climbing test remained the only independent predictor of cardiopulmonary complications after logistic regression analysis. In particular, only 6.5% of subjects climbing > 14 m vs 50% of those climbing < 12 m had major cardiopulmonary complications. We expanded their series and reported on a series including 640 major anatomic lung resections (lobectomy and pneumonectomy).<sup>139</sup> Compared with patients climbing > 22 m, those unable to climb 12 m had an incidence of cardiopulmonary complications and mortality of 2.5- and 13-fold higher, respectively. The mortality rate in this low-performing group (climbing < 12 m) was 13%. In a group of patients with a PPO FEV<sub>1</sub> < 40% or PPO DLCO < 40% or both, no death was observed among those climbing > 22 m, whereas the mortality was 20% among such patients unable to climb 12 m.

A high correlation was found between altitude climbed and  $\dot{V}O_{2peak}$  measured during the test ( $r = 0.7$ ).<sup>174</sup> The cutoff of 22 m had a positive predictive value of 86% to predict a  $\dot{V}O_{2peak}$  of 15 mL/kg/min. However, there are limitations to the usefulness of stair climbing. It has not been performed in a standardized manner. The duration of stair climbing, speed of ascent, number of steps per flight, height of each step, and criteria for stopping the test have varied from study to study. In an attempt to provide a method of standardization, Koegelenberg and colleagues<sup>175</sup> proposed using the speed of ascent, in addition to altitude; however, others have not found this parameter predictive of complications.<sup>176</sup> Patients with comorbid conditions (eg, musculoskeletal disease, neurologic abnormalities, peripheral vascular insufficiency, and others) may be unable to perform the test. Brunelli and colleagues<sup>177,178</sup> found that patients unable to perform stair climbing because of comorbid conditions had a fourfold higher risk of postoperative mortality compared with those able to perform the test (16% vs 4%). Other surrogate tests for CPET are the shuttle walk test (SWT) and the 6-min walk, but data on the value of these tests in predicting  $\dot{V}O_{2max}$  are limited.<sup>179</sup> The SWT requires that patients walk back and forth between two markers set 10 m apart. The walking speed is paced by an audio signal and the walking speed is increased each minute in a graded fashion. The end of the test occurs when the patient is too breathless to maintain the required speed. In one study, inability to complete 25 shuttles on two occasions suggested a  $\dot{V}O_{2max}$  < 10 mL/kg/min<sup>180</sup>; however, other investigations were not able to find an association between shuttle walk distance and postoperative complications.<sup>181</sup> Nevertheless, SWT distance

significantly correlated with  $\dot{V}O_{2peak}$  ( $r = 0.67$ ).<sup>157</sup> All patients who walked > 400 m at the SWT had a  $\dot{V}O_{2peak}$  measured at CPET > 15 mL/kg/min. On the other hand, nine of 17 patients who walked < 250 m had a  $\dot{V}O_{2peak}$  > 15 mL/kg/min, indicating that SWT tends to underestimate exercise capacity at the lower range compared with  $\dot{V}O_{2peak}$  measured with CPET.

In a more recent article, Benzo and Sciurba<sup>182</sup> found a high correlation between each level of the SWT and the oxygen consumption measured during the test. The cutoff of 25 shuttles had 90% positive predictive value for predicting a  $\dot{V}O_{2peak}$  > 15 mL/kg/min. For the 6-min walk, patients are instructed to walk as far as possible in the time allotted. Rest during the test is permissible. Interpretation of the distance walked in 6 min is currently not well standardized<sup>183</sup> and the few studies evaluating this test in lung resection candidates reported conflicting results.<sup>184</sup> The European guidelines do not recommend using this test for the functional evaluation of patients considered for lung surgery.<sup>18</sup>

### 3.6 Exercise Oxygen Desaturation

The SWT and the 6-min walk test may be more effective than CPET in identifying patients who desaturate during exercise.<sup>185</sup> The value of this observation, though, is unclear. Greater than 4% desaturation during exercise has been reported to indicate an increased risk of perioperative complications.<sup>114,116,186</sup> However, a study from the United Kingdom reported similar perioperative complication rates for patients who desaturated > 4% on a SWT and those who did not.<sup>181</sup> Similar nonunivocal findings were reported by using other forms of exercise. Three studies<sup>176,187,188</sup> used stair climbing as exercise tests and found that exercise oxygen desaturation was associated with increased risk of complications, such as postoperative respiratory failure, need for ICU admission, prolonged hospital stay, home oxygen requirement, and mortality. On the other hand, Varela and colleagues<sup>189</sup> did not find an association between oxygen desaturation below 90% during standardized incremental cycle-ergometry and postoperative cardiopulmonary morbidity.

### 3.7 Composite Scores

Investigators have proposed using composite scores to predict perioperative complications. Epstein's group<sup>158</sup> developed the multifactorial cardiopulmonary risk index, an empirically derived score based on points awarded for cardiac and pulmonary risk. A strong association between this score and postoperative complications in a group of 42 patients was shown. Birim et al<sup>154</sup> found that patients with more

comorbid conditions, identified by the Charlson comorbidity index, were also more likely to have major complications following lung cancer resection. Melendez and colleagues<sup>190</sup> used regression analysis to develop the predictive respiratory complication quotient, which is based on the % PPO FEV<sub>1</sub>, % PPO DLCO, and oxygenation. This score was also effective in identifying patients at increased risk of perioperative complications. Brunelli et al<sup>191</sup> adapted the physiologic and operative severity score for the enumeration of mortality and morbidity, a score originally used for general surgery issues, to evaluate post-lung resection problems. They suggested that this score might be a useful method for comparing the complication rates among different institutions. Ferguson and Durkin<sup>192</sup> developed a simple score based on the FEV<sub>1</sub>, DLCO, and age of the patient, which seems to compare favorably with other scoring systems<sup>158,191</sup> and is easy to administer. Data from national or international organizations were used to develop more reliable risk models. The ESTS proposed a model for in-hospital mortality (ESOS) incorporating two factors, age and PPO FEV<sub>1</sub>.<sup>193</sup> Similarly, the STS generated a risk model for predicting mortality and major morbidity.<sup>156</sup> Finally, the French Society of Thoracic and Cardiovascular Surgery published the Thoracocore, a multifactorial index to predict mortality following thoracic surgery.<sup>194</sup> Although useful for risk stratification and benchmarking in specific groups of patients, scoring systems generally lack adequate accuracy for assigning specific risk to individual patients. As suggested by previous guidelines,<sup>23</sup> caution should therefore be used in individual patient selection.

### 3.8 Arterial Blood Gas Tensions

Historically, hypercapnia (PaCO<sub>2</sub> > 45 mm Hg) has been quoted as an exclusion criterion for lung resection.<sup>195,196</sup> This recommendation was made on the basis of the association of hypercapnia with poor ventilatory function.<sup>197</sup> The few studies that address this issue, however, suggest that preoperative hypercapnia is not an independent risk factor for increased perioperative complications. Stein et al<sup>198</sup> showed that hypercapnia was associated with serious postoperative respiratory difficulties in five patients, but there were no deaths, despite a PaCO<sub>2</sub> > 45 mm Hg. Morice et al<sup>160</sup> reported on three patients with preoperative hypercapnia who survived curative-intent lung cancer surgery. In two series of patients with lung cancer undergoing surgery,<sup>199,200</sup> perioperative complications were not higher in patients with preoperative hypercapnia. Preoperative hypoxemia, defined as an arterial oxygen saturation < 90%, has been associated with an increased risk of postoperative complications.<sup>185</sup>

## 3.9 Recommendations

**3.9.1. In patients with lung cancer being considered for surgery who walk < 25 shuttles (or < 400m) on the SWT or climb < 22m at symptom limited stair climbing test, performance of a formal CPET with measurement of  $\dot{V}O_{2\max}$  is recommended (Grade 1C).**

*Remark:* Walking < 25 shuttles (or < 400 m) on the SWT or climbing < 22 m at symptom limited stair climbing test suggests an increased risk for perioperative death and cardiopulmonary complications with anatomic lung resection.

**3.9.2. In patients with lung cancer being considered for surgery and a  $\dot{V}O_{2\max}$  < 10mL/kg/min or < 35% predicted it is recommended that they are counseled about minimally invasive surgery, sublobar resections or nonoperative treatment options for their lung cancer (Grade 1C).**


*Remark:* a  $\dot{V}O_{2\max}$  < 10mL/kg/min or < 35% predicted indicates a high risk for perioperative death and cardiopulmonary complications with major anatomic lung resection through thoracotomy.

*Remark:* For values of  $\dot{V}O_{2\max}$  in the range of 10 to 15 mL/kg/min an increased risk of mortality is expected. However, data are less definitive for making decisions based solely on those values without taking into account other factors like PPO FEV<sub>1</sub> and DLCO as well as patient comorbidities.

## 4.0 FUNCTION ALGORITHM

We developed a functional algorithm based on the best available scientific evidence and consensus opinion of experts (Fig 2). Patients should be submitted to a preliminary cardiac evaluation (Fig 1). If the patient is deemed to be at increased cardiac risk, he or she should be managed according to American Heart Association/American College of Cardiology guidelines and further reevaluated. If the patient's cardiac evaluation turns out negative, or positive with low risk, he or she can proceed to pulmonary function evaluation and calculation of PPO pulmonary functions. The FEV<sub>1</sub> and DLCO should be measured in all patients and PPO values calculated. Patients with both a PPO FEV<sub>1</sub> and a PPO DLCO > 60% are regarded as at low risk for surgery. Patients with either a PPO FEV<sub>1</sub> or a PPO DLCO between 30% and 60% should perform a low technology exercise test as a screening test. If the performance at the low technology exercise test is satisfactory, patients are regarded as at moderate risk. A CPET is indicated if

**FIGURE 2.** [Section 4.0] Physiologic evaluation resection algorithm. (a) For pneumonectomy candidates, we suggest to use Q scan to calculate predicted postoperative values of FEV1 or DLCO (PPO values = preoperative values  $\times$  (1 – fraction of total perfusion for the resected lung), where the preoperative values are taken as the best measured postbronchodilator values. For lobectomy patients, segmental counting is indicated to calculate predicted postoperative values of FEV1 or DLCO (PPO values = preoperative values  $\times$  (1 – y/z), where the preoperative values are taken as the best measured postbronchodilator value and the number of functional or unobstructed lung segments to be removed is y and the total number of functional segments is z. (b) PpoFEV1 or ppoDLCO cut off values of 60% predicted values has been chosen based on indirect evidences and expert consensus opinion. (c) For patients with a positive high-risk cardiac evaluation deemed to be stable to proceed to surgery we suggest to perform both pulmonary function tests and cardiopulmonary exercise test for a more precise definition of risk. (d) Definition of risk: Low risk: The expected risk of mortality is below 1%. Major anatomic resections can be safely performed in this group. Moderate risk: Morbidity and mortality rates may vary according to the values of split lung functions, exercise tolerance and extent of resection. Risks and benefits of the operation should be thoroughly discussed with the patient. High risk: The risk of mortality after standard major anatomic resections may be higher than 10%. Considerable risk of severe cardiopulmonary morbidity and residual functional loss is expected. Patients should be counseled about alternative surgical (minor resections or minimally invasive surgery) or nonsurgical options. ppoDLCO = predicted postoperative diffusing capacity for carbon monoxide; ppoDLCO% = percent predicted postoperative diffusing capacity for carbon monoxide; ppoFEV1 = predicted postoperative FEV1; ppoFEV1% = percent predicted postoperative FEV1; SCT = stair climb test; SWT = shuttle walk test; VO2max = maximal oxygen consumption. See Figure 1 legend for expansion of other abbreviations.



PPO FEV<sub>1</sub> or PPO DLCO are < 30% or when performance in the stair-climbing test or the SWT is not satisfactory (ie, height reached in stair-climbing test < 22 m or a shuttle walk distance < 400 m). A  $\dot{V}O_{2peak}$  < 10 mL/kg/min or 35% predicted indicates a high risk for major anatomic resection through thoracotomy. Conversely, a  $\dot{V}O_{2peak}$  > 20 mL/kg/min or 75% predicted indicate a low risk. To ensure reliability

of results, a CPET must be performed according to the recommendations published by the American Thoracic Society/ACCP statement on CPET.<sup>201</sup>

Some patients are unable to perform some or all types of exercise tests for incapacitating comorbidities. These patients may have an increased risk of mortality following major anatomic resections.<sup>177</sup> They should be evaluated carefully based on the available



cardiac and pulmonary parameters and should be regarded as high-risk patients.

## 5.0 RISK OF LONG-TERM PULMONARY EFFECTS FOLLOWING RESECTION

A significant limitation to addressing the potential disabling long-term effects of lung resections is that studies providing objective measures such as pulmonary function tests or exercise capacity typically do not go beyond 6 months. Therefore, any disabling sequelae beyond this period truly remain understudied. With this limitation in mind, some general observations may be made. Following lung resection, lung function will decrease initially. Following thoracotomy, FEV<sub>1</sub> appears to nadir immediately after surgery.<sup>133,135,136</sup> Early investigators in this field suggested that a postoperative FEV<sub>1</sub> < 0.8 L was prohibitive to resection, given the unacceptable incidence of hypercapnia and pulmonary disability.<sup>202</sup> Ultimately though, the factors that contribute to long-term pulmonary disability, either individually or in concert, remain largely unknown. This makes predicting who exactly will suffer long-term pulmonary disability following lobectomy or pneumonectomy largely speculative. Some data exist regarding compromised pulmonary function following either a lobectomy or a pneumonectomy, but extrapolating these data to true long-term pulmonary disability is not possible with the existing data.

For a lobectomy, by 6 months postoperatively, the FEV<sub>1</sub> recovers partially so that there is a deficit from the preoperative FEV<sub>1</sub> of between 9% and 11%. In a prospective study, Brunelli and associates<sup>105</sup> demonstrated that recovery of preoperative FEV<sub>1</sub> and DLCO to the levels described in the previous reports at 6 months is achievable by 3 months following lobectomy. Exercise capacity as measured by  $\dot{V}O_2\text{max}$  will also decrease following lung resection, and for lobectomy this decrease has been observed to be between 0% and 13%.<sup>203,204</sup> The most common limiting symptom in postoperative exercise studies has been leg discomfort, rather than dyspnea.<sup>204,205</sup> Bolliger et al<sup>204</sup> found that exercise was limited by leg muscle fatigue in 53% of patients preoperatively, and this observation remained following lobectomy.

For pneumonectomy, the FEV<sub>1</sub> recovery at 6 months is markedly less and ranges between 34% and 41%.<sup>203,204,206</sup> In a prospective study by Brunelli et al,<sup>105</sup> the recovery of the deficit in FEV<sub>1</sub> was 66% of the preoperative value, whereas the DLCO recovery was 80% of baseline. This discrepant observation from their patients undergoing lobectomy may have been secondary to a relatively small percentage of patients undergoing pneumonectomy being included in their

prospective study. Following pneumonectomy, and similar to that observed for other pulmonary function tests, the deficit in  $\dot{V}O_2\text{max}$  does not become restored to preoperative values and remains between 20% and 28%.<sup>204,205</sup> Unlike the case for lobectomy, following pneumonectomy there is a switch to dyspnea as the limiting factor (61% of patients at 3 months and 50% at 6 months after resection), rather than leg muscle fatigue.

Unfortunately, few data describing changes in quality of life following curative-intent lung resection are available. Among patients with COPD, the preoperative pulmonary status appears to impact quality of life in the more acute perioperative period in that mechanical ventilation and need for tracheostomy occur with greater frequency than in those without COPD.<sup>96</sup> A cross-sectional survey examined respiratory symptoms and quality of life in 142 long-term survivors of non-small cell lung cancer.<sup>207</sup> Most of these patients (74%) had undergone a lobectomy, with 12% having had a pneumonectomy and 11% a wedge resection. The most commonly reported postoperative respiratory symptom was dyspnea, but cough and wheeze were also described frequently.

## 6.0 RISK OF LONG-TERM PULMONARY DISABILITY WITH NEOADJUVANT THERAPY

The risks associated with neoadjuvant therapy that result in long-term pulmonary disability remain a topic that is not well understood. Furthermore, the existing evidence associated with the negative long-term pulmonary effects of neoadjuvant chemotherapy with and without radiation therapy is limited.

Diffusion capacity appears to be the pulmonary function test that is most affected by the use of neoadjuvant chemotherapy. One prospective randomized controlled trial has evaluated the effect of neoadjuvant therapy in this regard, but the long-term effect on pulmonary disability was not presented.<sup>208</sup> Differing regimens of neoadjuvant gemcitabine-chemotherapy were associated with a mean decrease in the hemoglobin-adjusted DLCO of 8%. In fact, 27% of the original 87 patients met the criteria for pulmonary toxicity, and 11% of the patients had a postneoadjuvant DLCO of  $\leq 40\%$ . Ultimately, however, of the 15% of patients who were deemed to have a significant reduction in their DLCO, none were precluded from undergoing surgical resection.<sup>208</sup> Other retrospective studies have demonstrated similar findings in which neoadjuvant therapy has negatively impacted diffusion capacity among other pulmonary function tests.<sup>115,209,210</sup> Collectively, although all these studies have demonstrated that there is a detrimental effect on pulmonary function tests following neoadjuvant therapy, only limited

data exist regarding the impact of these pulmonary function alterations in the long-term setting.<sup>211</sup> Margaritora et al<sup>211</sup> described a significant increase in DLCO at the 1-year mark following neoadjuvant chemoradiation therapy. Because other studies have demonstrated a decrease in diffusion capacity shortly after the completion of neoadjuvant therapy and surgery,<sup>115,209,210</sup> an increase in DLCO suggests that recovery of damaged parenchyma may be occurring in the longer-term period. Although DLCO has been associated with the development of postoperative morbidity and mortality following neoadjuvant therapy and surgery,<sup>210,212</sup> no definitive factors that predict long-term pulmonary disability have been firmly identified. Fujita et al<sup>213</sup> demonstrated that radiation therapy doses of > 45 Gy were predictive of postoperative morbidity, but no factors that were associated with any longer-term sequelae were described. Ultimately, predicting long-term pulmonary disability remains an unresolved issue and an area for potential study.

## 6.1 Recommendation

**6.1.1. In patients with lung cancer being considered for surgery who undergo neoadjuvant therapy, it is suggested that repeat pulmonary function testing with diffusion capacity be performed after completion of neoadjuvant therapy (Grade 2C).**

## 7.0 METHODS TO REDUCE PERIOPERATIVE RISKS AND LONG-TERM PULMONARY DISABILITY

### 7.1 Lung Volume Reduction Surgery

Lung volume reduction surgery (LVRS) for patients with severe emphysema has been shown in a large prospective, randomized controlled trial to provide a survival advantage in selected patients with predominantly upper-lobe emphysema and low exercise capacity.<sup>214</sup> Anecdotal experience has shown that lung resected during LVRS has occasionally contained unsuspected lung cancers.<sup>215,216</sup> Patients eligible for LVRS who also have lung cancer represent a unique subset of individuals. If traditional criteria are used to determine suitability for resection, most LVRS candidates with lung cancer would not be considered acceptable to proceed with resection. However, multiple case series suggest that patients with extremely poor lung function can tolerate combined LVRS and resection of the lung cancer with an acceptable mortality rate and surprisingly good postoperative outcomes.<sup>106,217-225</sup> Others have also described curative-intent surgical resections among patients with LVRS and have found significant and lasting improvements in FEV<sub>1</sub>.<sup>224,225</sup>

In terms of mid-term and long-term survival, encouraging results have been observed among patients undergoing LVRS and lung cancer resections.<sup>215,218,224</sup> One prospective case-control study found that patients with heterogeneous upper-lobe emphysema who underwent upper lobectomy for known stage I and II lung cancer had a respectable, but lower overall, survival compared with those patients undergoing conventional LVRS resections (57 months vs 88 months,  $P = .06$ ).<sup>218</sup> In contrast, Nakajima et al<sup>226</sup> reported that patients with severe COPD undergoing curative-intent resections for their lung cancers had a worse 5-year survival (24% vs 59%,  $P < .0001$ ) relative to their patients undergoing more straightforward LVRS. However, this study was skewed in that preoperative baseline difference in smoking status, pulmonary function tests, and COPD grade existed favoring the LVRS population. Although indications for combined LVRS and lung cancer resection are still evolving, the most promising candidates appear to be patients who have a cancer in the upper lobe that is also affected by emphysema and who would otherwise meet the criteria for LVRS (ie, DLCO and FEV<sub>1</sub> > 20% predicted). Although some have suggested a more aggressive approach,<sup>227</sup> enthusiasm for recruiting patients with relatively preserved lung should be tempered by the fact that conclusions regarding the differences in long-term outcomes between LVRS alone and LVRS with patients with lung cancer may have compared different populations at baseline.

### 7.2 Smoking Cessation

Retrospective studies have demonstrated that the timing of tobacco cessation prior to surgery, in general, has a minimal impact on postoperative pulmonary complications.<sup>228,229</sup> The combination of smoking cessation and lung cancer surgery is not associated with differences in pulmonary function tests postoperatively.<sup>229</sup> Another retrospective study of 288 consecutive patients undergoing pulmonary surgery suggested that smoking abstinence of at least 4 weeks may be associated with reduced perioperative respiratory complications.<sup>230</sup> An analysis of nearly 8,000 patients from the STS database demonstrated that the perioperative mortality among current and past smokers vs nonsmokers is significantly higher (1.5% vs 0.3%,  $P = .001$ ). In fact, a general trend for decreasing perioperative mortality was associated with length of cessation prior to surgery.<sup>231</sup> Similar findings have been reported elsewhere among former and current smokers.<sup>232</sup> Cumulatively, tobacco dependence cessation appears to be advantageous in reducing short-term outcomes associated with lung cancer resections.

With respect to long-term survival, 5- and 10-year survivals have been found to be worse for stage I lung

cancers among current smokers compared with former smokers and nonsmokers.<sup>232</sup> Prospective controlled trials are needed to more clearly define the effect smoking cessation preoperatively may have on reducing perioperative problems. There already are data that demonstrate it is associated with an improved quality of life and cost effectiveness.<sup>233</sup> Despite the limited amount of data that currently exists, smoking cessation should be encouraged at the time of diagnosis of lung cancer because early data suggest that perioperative outcomes and long-term survival are better when compared with those who have not ceased tobacco use. Additionally, there may be a reduction in the development of metachronous tumors (see articles on by Leone et al<sup>234</sup> tobacco treatment and by Colt et al<sup>235</sup> follow-up and surveillance in the ACCP Lung Cancer Guidelines).

### 7.3 Pulmonary Rehabilitation

As yet, there are no robust data to recommend the routine use of preoperative pulmonary rehabilitation for patients with lung cancer. There is, however, a growing body of evidence that suggests that preoperative conditioning may be advantageous.<sup>236-238</sup> In the National Emphysema Treatment Trial, all patients underwent pulmonary rehabilitation prior to randomization to either medical treatment or LVRS. Pulmonary rehabilitation provided important benefits in dyspnea, quality of life, and exercise ability.<sup>236</sup> Weinstein et al<sup>237</sup> demonstrated that a preoperative regimen was inversely proportional to patients' length of stay. Bobbio et al<sup>238</sup> demonstrated that their preoperative pulmonary rehabilitation program resulted in an increase in  $\dot{V}O_{2\max}$  at the anaerobic threshold and that there was an increase in workload. Other data, however, are not as supportive, showing that cardiopulmonary performance is not significantly altered.<sup>239</sup> Ultimately, the absence of randomized controlled trial data regarding preoperative pulmonary rehabilitation allows for only the suggestion that it will be beneficial to the patients undergoing it. In the postoperative setting, information is emerging that initiating an inpatient regimen following a lung resection is immediately beneficial for patients. These inpatient programs have been associated with improvements in exercise performance, symptoms, and pulmonary function tests (FEV<sub>1</sub>).<sup>240,241</sup> Secondary gains, in the form of improved quadriceps strength, without improvements in objective exercise performance measures, have been found to occur with pulmonary rehabilitation programs.<sup>242</sup> Improvements in exercise performance without any objective improvements in pulmonary function tests have also been observed with postoperative pulmonary rehabilitation.<sup>243</sup> Even in the absence of a formalized rehabilitation program

per se, planned ambulation within 4 h following a resection has been associated with improved oxygenation and lower external oxygen requirements.<sup>244</sup> Although the data on pulmonary rehabilitation are difficult to quantify or standardize, what is available seems to confirm intuition that pulmonary rehabilitation following lung cancer surgery is of benefit to patients, albeit in differing forms.

### 7.4 Recommendations

**7.4.1. In patients with lung cancer in an area of upper lobe emphysema who are candidates for LVRS, combined LVRS and lung cancer resection is suggested (Grade 2C).**

**7.4.2. In all patients with lung cancer being considered for surgery who are actively smoking, tobacco dependence treatment is recommended (Grade 1C).**

*Remark:* Smoking cessation is associated with short-term perioperative and long-term survival benefits (see also specific recommendations in chapter 6, 3.1.1, 3.1.2, 3.1.3).

**7.4.3. In patients with lung cancer being considered for surgery and deemed at high risk (as defined by the proposed functional algorithm, ie, PPO FEV<sub>1</sub> or PPO DLCO < 60% and  $\dot{V}O_{2\max}$  < 10 mL/kg/min or < 35%), preoperative or postoperative pulmonary rehabilitation is recommended (Grade 1C).**

## 8.0 SUMMARY

Patients with lung cancer often have concomitant diffuse parenchymal and/or obstructive airway disease and atherosclerotic cardiovascular disease as a consequence of their smoking habit. These diseases may place these patients at increased risk of perioperative complications, including death and long-term pulmonary disability after lung cancer resection. A careful preoperative physiologic assessment is useful to identify those patients at increased risk with standard lung cancer resection and to enable an informed decision by the patient about the appropriate therapeutic approach to treating their lung cancer. This preoperative risk assessment must be placed in the context that surgery for early-stage lung cancer is the most effective currently available treatment of this disease.

### ACKNOWLEDGMENTS

**Author contributions:** Dr Brunelli had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.



**Dr Brunelli:** contributed to the review of the final draft and formatting of the original algorithms and as a panelist.

**Dr Kim:** contributed to the article as a panelist.

**Dr Berger:** contributed to the article as a panelist.

**Dr Addrizzo-Harris:** contributed to the article as the topic editor.

**Financial/nonfinancial disclosures:** The authors have reported to *CHEST* that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

**Role of Sponsors:** The American College of Chest Physicians was solely responsible for the development of these guidelines. The remaining supporters played no role in the development process. External supporting organizations cannot recommend panelists or topics, nor are they allowed prepublication access to the manuscripts and recommendations. Further details on the Conflict of Interest Policy are available online at <http://chestnet.org>.

**Endorsements:** This guideline is endorsed by the European Society of Thoracic Surgeons, Oncology Nursing Society, American Association for Bronchology and Interventional Pulmonology, and the Society of Thoracic Surgeons.

## REFERENCES

1. Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5)(suppl):41S-50S.
2. Beckles MA, Spiro SG, Colice GL, Rudd RM; American College of Chest Physicians. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. *Chest*. 2003;123(suppl 1):105S-114S.
3. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT; American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). *Chest*. 2007;132(suppl 3):161S-177S.
4. Burke JR, Duarte IG, Thourani VH, Miller JI Jr. Preoperative risk assessment for marginal patients requiring pulmonary resection. *Ann Thorac Surg*. 2003;76(5):1767-1773.
5. Ferguson MK. Preoperative assessment of pulmonary risk. *Chest*. 1999;115(suppl 5):58S-63S.
6. Reilly JJ Jr. Evidence-based preoperative evaluation of candidates for thoracotomy. *Chest*. 1999;116(suppl 6):474S-476S.
7. Bolliger CT, Perruchoud AP. Functional evaluation of the lung resection candidate. *Eur Respir J*. 1998;11(1):198-212.
8. Bolliger CT, Koegelenberg CF, Kendal R. Preoperative assessment for lung cancer surgery. *Curr Opin Pulm Med*. 2005;11(4):301-306.
9. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. *Chest*. 2003;123(6):2096-2103.
10. Felip E, Stahel RA, Pavlidis N. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). *Ann Oncol*. 2005;16(suppl 1):i28-29.
11. Depierre A, Lagrange JL, Theobald S, et al; FNCLCC. Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000). *Br J Cancer*. 2003;89(suppl 1):S35-S49.
12. Lowe G, Twaddle S. The Scottish Intercollegiate Guidelines Network (SIGN): an update. *Scott Med J*. 2005;50(2):51-52.
13. Wood E. The National Comprehensive Cancer Network (NCCN). *J Med Libr Assoc*. 2004;92(3):382-383.
14. National Cancer Institute. Non-small cell lung cancer (PDQ): Treatment. National Cancer Institute website. <http://www.cancer.gov>. Accessed May 2005.
15. Central European Cooperative Oncology Group (CECOG); Advisory Committee on Collaboration with Industry in Medical Education of the European School of Oncology (ESO); Vienna Medical Association. Consensus on medical treatment of non-small cell lung cancer. *Lung Cancer*. 2002;38(suppl 3):S3-S7.
16. Baldwin DR, White B, Schmidt-Hansen M, Champion AR, Melder AM. Guideline Development Group. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. *BMJ*. 2011;342:d2110.
17. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. *Thorax*. 2010;65(suppl 3):iii1-27.
18. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). *Eur Respir J*. 2009;34(1):17-41.
19. Muers MF, Haward RA. Management of lung cancer. *Thorax*. 1996;51(6):557-560.
20. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. *Thorax*. 1996;51(6):564-568.
21. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. *Lung Cancer*. 2008;60(1):14-21.
22. Price A KG, Gregor A, Ironside J, Little F. The impact of multidisciplinary teams and site specialisation on the use of radiotherapy in elderly people with non-small cell lung cancer (NSCLC). *Radiotherapy and Oncology*. 2002;64(suppl 1):S80.
23. Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. *Br J Cancer*. 2005;93(9):977-978.
24. Bowen EF, Anderson JR, Roddie ME. Improving surgical resection rates in lung cancer without a two stop service. *Thorax*. 2003;58(4):368.
25. Davison AG, Eraut CD, Haque AS, et al. Telemedicine for multidisciplinary lung cancer meetings. *J Telemed Telecare*. 2004;10(3):140-143.
26. Boxer MM, Vinod SK, Shafiq J, Duggan KJ. Do multidisciplinary team meetings make a difference in the management of lung cancer? *Cancer*. 2011;117(22):5112-5120.
27. Freeman RK, Van Woerkom JM, Vyverberg A, Ascoti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. *Eur J Cardiothorac Surg*. 2010;38(1):1-5.
28. Dowie J, Wildman M. Choosing the surgical mortality threshold for high risk patients with stage Ia non-small cell lung cancer: insights from decision analysis. *Thorax*. 2002;57(1):7-10.
29. Pallis AG, Gridelli C, van Meerbeeck JP, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. *Ann Oncol*. 2010;21(4):692-706.
30. Bröck MV, Kim MP, Hooker CM, et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. *Ann Thorac Surg*. 2004;77(1):271-277.
31. Port JL, Kent M, Korst RJ, et al. Surgical resection for lung cancer in the octogenarian. *Chest*. 2004;126(3):733-738.
32. Allen MS, Darling GE, Pechet TT, et al; ACOSOG Z0030 Study Group. Morbidity and mortality of major pulmonary

- resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. *Ann Thorac Surg*. 2006;81(3):1013-1019.
33. Berry MF, Onaitis MW, Tong BC, Harpole DH, D'Amico TA. A model for morbidity after lung resection in octogenarians. *Eur J Cardiothorac Surg*. 2011;39(6):989-994.
  34. Cerfolio RJ, Bryant AS. Survival and outcomes of pulmonary resection for non-small cell lung cancer in the elderly: a nested case-control study. *Ann Thorac Surg*. 2006;82(2):424-429., discussion 429-430.
  35. Fanucchi O, Ambroggi MC, Dini P, et al. Surgical treatment of non-small cell lung cancer in octogenarians. *Interact Cardiovasc Thorac Surg*. 2011;12(5):749-753.
  36. Igai H, Takahashi M, Ohata K, et al. Surgical treatment for non-small cell lung cancer in octogenarians—the usefulness of video-assisted thoracic surgery. *Interact Cardiovasc Thorac Surg*. 2009;9(2):274-277.
  37. Matsuoka H, Okada M, Sakamoto T, Tsubota N. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. *Eur J Cardiothorac Surg*. 2005;28(3):380-383.
  38. Mun M, Kohno T. Video-assisted thoracic surgery for clinical stage I lung cancer in octogenarians. *Ann Thorac Surg*. 2008;85(2):406-411.
  39. Rivera C, Dahan M, Bernard A, Falcoz PE, Thomas P. Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. *Eur J Cardiothorac Surg*. 2011;39(6):981-986.
  40. Sawada S, Komori E, Nogami N, et al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. *Chest*. 2005;128(3):1557-1563.
  41. Brokx HA, Visser O, Postmus PE, Paul MA. Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. *J Thorac Oncol*. 2007;2(11):1013-1017.
  42. Dillman RO, Zusman DR, McClure SE. Surgical resection and long-term survival for octogenarians who undergo surgery for non-small-cell lung cancer. *Clin Lung Cancer*. 2009;10(2):130-134.
  43. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. *J Am Coll Surg*. 2007;205(6):729-734.
  44. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. *J Clin Oncol*. 2007;25(35):5570-5577.
  45. Dhand R. Aerosol therapy during mechanical ventilation: getting ready for prime time. *Am J Respir Crit Care Med*. 2003;168(10):1148-1149.
  46. Voltolini L, Rapicetta C, Ligabue T, Luzzi L, Scala V, Gotti G. Short- and long-term results of lung resection for cancer in octogenarians. *Asian Cardiovasc Thorac Ann*. 2009;17(2):147-152.
  47. Dominguez-Ventura A, Allen MS, Cassivi SD, Nichols FC III, Deschamps C, Pairolero PC. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection. *Ann Thorac Surg*. 2006;82(4):1175-1179.
  48. Brunelli A, Varela G, Salati M, et al. Recalibration of the revised cardiac risk index in lung resection candidates. *Ann Thorac Surg*. 2010;90(1):199-203.
  49. Brunelli A, Cassivi SD, Fibla J, et al. External validation of the recalibrated thoracic revised cardiac risk index for predicting the risk of major cardiac complications after lung resection. *Ann Thorac Surg*. 2011;92(2):445-448.
  50. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999;100(10):1043-1049.
  51. Fleisher LA, Beckman JA, Brown KA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation*. 2007;116(17):e418-e499.
  52. Poldermans D, Bax JJ, Boersma E, et al; Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery; European Society of Cardiology (ESC). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. *Eur Heart J*. 2009;30(22):2769-2812.
  53. Ferguson MK, Celauro AD, Vigneswaran WT. Validation of a modified scoring system for cardiovascular risk associated with major lung resection. *Eur J Cardiothorac Surg*. 2012;41(3):598-602.
  54. Eagle KA, Berger PB, Calkins H, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Circulation*. 2002;105(10):1257-1267.
  55. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med*. 2004;351(27):2795-2804.
  56. Poldermans D, Schouten O, Vidakovic R, et al; DECREASE Study Group. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. *J Am Coll Cardiol*. 2007;49(17):1763-1769.
  57. Douketis JD, Berger PB, Dunn AS, et al; American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest*. 2008;133(suppl 6):299S-339S.
  58. Cerfolio RJ, Minnich DJ, Bryant AS. General thoracic surgery is safe in patients taking clopidogrel (Plavix). *J Thorac Cardiovasc Surg*. 2010;140(5):970-976.
  59. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR; POBBLE trial investigators. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. *J Vasc Surg*. 2005;41(4):602-609.

60. Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. *Am Heart J*. 2006;152(5):983-990.
61. Devereaux PJ, Yang H, Yusuf S, et al; POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. *Lancet*. 2008;371(9627):1839-1847.
62. Poldermans D, Boersma E, Bax JJ, et al; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. *N Engl J Med*. 1999;341(24):1789-1794.
63. Pinkstaff S, Peberdy MA, Kontos MC, Fabiato A, Finucane S, Arena R. Usefulness of decrease in oxygen uptake efficiency slope to identify myocardial perfusion defects in men undergoing myocardial ischemic evaluation. *Am J Cardiol*. 2010;106(11):1534-1539.
64. Chaudhry S, Arena R, Wasserman K, et al. Exercise-induced myocardial ischemia detected by cardiopulmonary exercise testing. *Am J Cardiol*. 2009;103(5):615-619.
65. Chaudhry S, Arena RA, Hansen JE, et al. The utility of cardiopulmonary exercise testing to detect and track early-stage ischemic heart disease. *Mayo Clin Proc*. 2010;85(10):928-932.
66. Belardinelli R, Lacalaprice F, Carle F, et al. Exercise-induced myocardial ischaemia detected by cardiopulmonary exercise testing. *Eur Heart J*. 2003;24(14):1304-1313.
67. Martin-Ucar AE, Waller DA, Atkins JL, Swinson D, O'Byrne KJ, Peake MD. The beneficial effects of specialist thoracic surgery on the resection rate for non-small-cell lung cancer. *Lung Cancer*. 2004;46(2):227-232.
68. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. *Chest*. 1998;114(3):675-680.
69. Schipper PH, Diggs BS, Ungerleider RM, Welke KF. The influence of surgeon specialty on outcomes in general thoracic surgery: a national sample 1996 to 2005. *Ann Thorac Surg*. 2009;88(5):1566-1572.
70. Goodney PP, Lucas FL, Stukel TA, Birkmeyer JD. Surgeon specialty and operative mortality with lung resection. *Ann Surg*. 2005;241(1):179-184.
71. Farjah F, Flum DR, Varghese TK Jr, Symons RG, Wood DE. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. *Ann Thorac Surg*. 2009;87(4):995-1004.
72. Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. *Chest*. 1992;101(5):1332-1337.
73. Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. *Arch Surg*. 2003;138(7):721-725.
74. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. *N Engl J Med*. 2001;345(3):181-188.
75. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med*. 2002;346(15):1128-1137.
76. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. *N Engl J Med*. 2003;349(22):2117-2127.
77. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. *Surgery*. 2002;131(1):6-15.
78. Cheung MC, Hamilton K, Sherman R, et al. Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. *Ann Surg Oncol*. 2009;16(1):3-13.
79. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. *Ann Thorac Surg*. 2005;80(6):2051-2056.
80. Bilimoria KY, Bentrem DJ, Feinglass JM, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. *J Clin Oncol*. 2008;26(28):4626-4633.
81. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. *JAMA*. 1998;280(20):1747-1751.
82. Urbach DR, Bell CM, Austin PC. Differences in operative mortality between high- and low-volume hospitals in Ontario for 5 major surgical procedures: estimating the number of lives potentially saved through regionalization. *CMAJ*. 2003;168(11):1409-1414.
83. Freixinet JL, Julia-Serda G, Rodriguez PM, et al. Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spanish multicenter study of 2994 cases. *Eur J Cardiothorac Surg*. 2006;29(1):20-25.
84. Wouters MW, Siesling S, Jansen-Landheer ML, et al. Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands. *Eur J Surg Oncol*. 2010;36(suppl 1):S83-92.
85. Treasure T, Utley M, Bailey A. Assessment of whether in-hospital mortality for lobectomy is a useful standard for the quality of lung cancer surgery: retrospective study. *BMJ*. 2003;327(7406):73-75.
86. Simunovic M, Rempel E, Theriault ME, et al. Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. *Can J Surg*. 2006;49(4):251-258.
87. Finlayson EV, Birkmeyer JD. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. *J Am Coll Surg*. 2003;196(3):410-417.
88. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. *Ann Surg*. 2007;245(5):777-783.
89. Lien YC, Huang MT, Lin HC. Association between surgeon and hospital volume and in-hospital fatalities after lung cancer resections: the experience of an Asian country. *Ann Thorac Surg*. 2007;83(5):1837-1843.
90. Damhuis RAM, Schütte PR. Resection rates and postoperative mortality in 7,899 patients with lung cancer. *Eur Respir J*. 1996;9(1):7-10.
91. Cerfolio RJ, Bryant AS, Patel B, Bartolucci AA. Intercostal muscle flap reduces the pain of thoracotomy: a prospective randomized trial. *J Thorac Cardiovasc Surg*. 2005;130(4):987-993.
92. Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. *J Thorac Cardiovasc Surg*. 2010;139(2):366-378.
93. Swanson SJ, Herndon JE II, D'Amico TA, et al. Video-assisted thoracic surgery lobectomy: report of CALGB 39802—a prospective, multi-institution feasibility study. *J Clin Oncol*. 2007;25(31):4993-4997.
94. Melfi FM, Mussi A. Robotically assisted lobectomy: learning curve and complications. *Thorac Surg Clin*. 2008;18(3):289-295, vi-vii.
95. Berry MF, Villamizar-Ortiz NR, Tong BC, et al. Pulmonary function tests do not predict pulmonary complications after thoracoscopic lobectomy. *Ann Thorac Surg*. 2010;89(4):1044-1051.



96. Iwasaki A, Shirakusa T, Enatsu S, Maekawa S, Yoshida Y, Yoshinaga Y. Surgical treatment for lung cancer with COPD based on the global initiative for chronic obstructive lung disease (GOLD). *Thorac Cardiovasc Surg.* 2005;53(3):162-167.
97. Ferguson MK, Siddique J, Karrison T. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. *Eur J Cardiothorac Surg.* 2008;34(5):1085-1089.
98. Koizumi KHS, Haraguchi S, Hirata T, et al. Surgical treatment for lung cancer patients with poor pulmonary function. *Ann Thorac Cardiovasc Surg.* 2005;11(2):87-92.
99. Licker MJ, Widikker I, Robert J, et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. *Ann Thorac Surg.* 2006;81(5):1830-1837.
100. Magdeleinat P, Seguin A, Alifano M, Boubia S, Regnard JF. Early and long-term results of lung resection for non-small-cell lung cancer in patients with severe ventilatory impairment. *Eur J Cardiothorac Surg.* 2005;27(6):1099-1105.
101. Garzon JC, Ng CSH, Sihoe ADL, et al. Video-assisted thoracic surgery pulmonary resection for lung cancer in patients with poor lung function. *Ann Thorac Surg.* 2006;81(6):1996-2003.
102. Brunelli A, Al Refai M, Monteverde M, Sabbatini A, Xiumé F, Fianchini A. Predictors of early morbidity after major lung resection in patients with and without airflow limitation. *Ann Thorac Surg.* 2002;74(4):999-1003.
103. Linden PA, Bueno R, Colson YL, et al. Lung resection in patients with preoperative FEV1 < 35% predicted. *Chest.* 2005;127(6):1984-1990.
104. Sekine Y, Iwata T, Chiyo M, et al. Minimal alteration of pulmonary function after lobectomy in lung cancer patients with chronic obstructive pulmonary disease. *Ann Thorac Surg.* 2003;76(2):356-361.
105. Brunelli A, Xiumé F, Refai M, et al. Evaluation of expiratory volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis. *Chest.* 2007;131(1):141-147.
106. Edwards JG, Duthie DJR, Waller DA. Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patients with emphysema. *Thorax.* 2001;56(10):791-795.
107. Carretta A, Zannini P, Puglisi A, et al. Improvement of pulmonary function after lobectomy for non-small cell lung cancer in emphysematous patients. *Eur J Cardiothorac Surg.* 1999;15(5):602-607.
108. Korst RJ, Ginsberg RJ, Ailawadi M, et al. Lobectomy improves ventilatory function in selected patients with severe COPD. *Ann Thorac Surg.* 1998;66(3):898-902.
109. Santambrogio L, Nosotti M, Baisi A, Ronzoni G, Bellaviti N, Rosso L. Pulmonary lobectomy for lung cancer: a prospective study to compare patients with forced expiratory volume in 1 s more or less than 80% of predicted. *Eur J Cardiothorac Surg.* 2001;20(4):684-687.
110. Baldi S, Ruffini E, Harari S, et al. Does lobectomy for lung cancer in patients with chronic obstructive pulmonary disease affect lung function? A multicenter national study. *J Thorac Cardiovasc Surg.* 2005;130(6):1616-1622.
111. Brunelli A, Refai M, Salati M, Xiumé F, Sabbatini A. Predicted versus observed FEV1 and DLCO after major lung resection: a prospective evaluation at different post-operative periods. *Ann Thorac Surg.* 2007;83(3):1134-1139.
112. Brunelli A, Sabbatini A, Xiumé F, et al. A model to predict the decline of the forced expiratory volume in one second and the carbon monoxide lung diffusion capacity early after major lung resection. *Interact Cardiovasc Thorac Surg.* 2005;4(1):61-65.
113. Ferguson MK, Little L, Rizzo L, et al. Diffusing capacity predicts morbidity and mortality after pulmonary resection. *J Thorac Cardiovasc Surg.* 1988;96(6):894-900.
114. Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. *Am Rev Respir Dis.* 1989;139(4):902-910.
115. Cerfolio RJ, Bryant AS. Different diffusing capacity of the lung for carbon monoxide as predictors of respiratory morbidity. *Ann Thorac Surg.* 2009;88(2):405-410.
116. Pierce RJ, Copland JM, Sharpe K, Barter CE. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. *Am J Respir Crit Care Med.* 1994;150(4):947-955.
117. Ferguson MK, Reeder LB, Mick R. Optimizing selection of patients for major lung resection. *J Thorac Cardiovasc Surg.* 1995;109(2):275-281.
118. Santini M, Fiorello A, Vicidomini G, Di Crescenzo VG, Laperuta P. Role of diffusing capacity in predicting complications after lung resection for cancer. *Thorac Cardiovasc Surg.* 2007;55(6):391-394.
119. Brunelli A, Refai MA, Salati M, Sabbatini A, Morgan-Hughes NJ, Rocco G. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection. *Eur J Cardiothorac Surg.* 2006;29(4):567-570.
120. Ferguson MK, Vigneswaran WT. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. *Ann Thorac Surg.* 2008;85(4):1158-1164.
121. Liptay MJ, Basu S, Hoaglin MC, et al. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. *J Surg Oncol.* 2009;100(8):703-707.
122. Ferguson M, Dignam JJ, Siddique J, Vidneswaran WT, Celauro AD. Diffusing capacity predicts long-term survival after lung resection for cancer. *Eur J Cardiothorac Surg.* 2012;41(5):e81-e86.
123. Handy JR Jr, Asaph JW, Skokan L, et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. *Chest.* 2002;122(1):21-30.
124. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J.* 2005;26(4):720-735.
125. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J.* 2005;26(2):319-338.
126. Bolliger CT, Gückel C, Engel H, et al. Prediction of functional reserves after lung resection: comparison between quantitative computed tomography, scintigraphy, and anatomy. *Respiration.* 2002;69(6):482-489.
127. Alam N, Park BJ, Wilton A, et al. Incidence and risk factors for lung injury after lung cancer resection. *Ann Thorac Surg.* 2007;84(4):1085-1091.
128. Martin-Ucar AE, Fareed KR, Nakas A, Vaughan P, Edwards JG, Waller DA. Is the initial feasibility of lobectomy for stage I non-small cell lung cancer in severe heterogeneous emphysema justified by long-term survival? *Thorax.* 2007;62(7):577-580.
129. Lau KKW, Martin-Ucar AE, Nakas A, Waller DA. Lung cancer surgery in the breathless patient—the benefits of avoiding the gold standard. *Eur J Cardiothorac Surg.* 2010;38(1):6-13.
130. Endoh H, Tanaka S, Yajima T, et al. Pulmonary function after pulmonary resection by posterior thoracotomy, anterior thoracotomy or video-assisted surgery. *Eur J Cardiothorac Surg.* 2010;37(5):1209-1214.

131. Bobbio A, Chetta A, Carbognani P, et al. Changes in pulmonary function test and cardio-pulmonary exercise capacity in COPD patients after lobar pulmonary resection. *Eur J Cardiothorac Surg.* 2005;28(5):754-758.
132. Kushibe K, Takahama M, Tojo T, Kawaguchi T, Kimura M, Taniguchi S. Assessment of pulmonary function after lobectomy for lung cancer—upper lobectomy might have the same effect as lung volume reduction surgery. *Eur J Cardiothorac Surg.* 2006;29(6):886-890.
133. Varela G, Brunelli A, Rocco G, Jiménez MF, Salati M, Gatani T. Evidence of lower alteration of expiratory volume in patients with airflow limitation in the immediate period after lobectomy. *Ann Thorac Surg.* 2007;84(2):417-422.
134. Luzzi L, Tenconi S, Voltolini L, et al. Long-term respiratory functional results after pneumonectomy. *Eur J Cardiothorac Surg.* 2008;34(1):164-168.
135. Varela G, Brunelli A, Rocco G, et al. Predicted versus observed FEV1 in the immediate postoperative period after pulmonary lobectomy. *Eur J Cardiothorac Surg.* 2006;30(4):644-648.
136. Varela G, Brunelli A, Rocco G, et al. Measured FEV1 in the first postoperative day, and not ppoFEV1, is the best predictor of cardio-respiratory morbidity after lung resection. *Eur J Cardiothorac Surg.* 2007;31(3):518-521.
137. Brunelli A, Varela G, Rocco G, et al. A model to predict the immediate postoperative FEV1 following major lung resections. *Eur J Cardiothorac Surg.* 2007;32(5):783-786.
138. Puente-Maestú L, Villar F, González-Casurrán G, et al. Early and long-term validation of an algorithm assessing fitness for surgery in patients with postoperative FEV<sub>1</sub> and diffusing capacity of the lung for carbon monoxide < 40%. *Chest.* 2011;139(6):1430-1438.
139. Brunelli A, Refai M, Xiumé F, et al. Performance at symptom-limited stair-climbing test is associated with increased cardiopulmonary complications, mortality, and costs after major lung resection. *Ann Thorac Surg.* 2008;86(1):240-247.
140. Holden DA, Rice TW, Stelmach K, Meeker DP. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. *Chest.* 1992;102(6):1774-1779.
141. Bechard D, Wetstein L. Assessment of exercise oxygen consumption as preoperative criterion for lung resection. *Ann Thorac Surg.* 1987;44(4):344-349.
142. Olsen GN, Weiman DS, Bolton JWR, et al. Submaximal invasive exercise testing and quantitative lung scanning in the evaluation for tolerance of lung resection. *Chest.* 1989;95(2):267-273.
143. Benzo R, Kelley GA, Recchi L, Hofman A, Sciarba F. Complications of lung resection and exercise capacity: a meta-analysis. *Respir Med.* 2007;101(8):1790-1797.
144. Loewen GM, Watson D, Kohman L, et al; Cancer and Leukemia Group B. Preoperative exercise Vo<sub>2</sub> measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238. *J Thorac Oncol.* 2007;2(7):619-625.
145. Bayram AS, Candan T, Gebitekin C. Preoperative maximal exercise oxygen consumption test predicts postoperative pulmonary morbidity following major lung resection. *Respirology.* 2007;12(4):505-510.
146. Torchio R, Guglielmo M, Giardino R, et al. Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer. *Eur J Cardiothorac Surg.* 2010;38(1):14-19.
147. Bobbio A, Chetta A, Internullo E, et al. Exercise capacity assessment in patients undergoing lung resection. *Eur J Cardiothorac Surg.* 2009;35(3):419-422.
148. Brunelli A, Belardinelli R, Refai M, et al. Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection. *Chest.* 2009;135(5):1260-1267.
149. Walsh GL, Morice RC, Putnam JB Jr, et al. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. *Ann Thorac Surg.* 1994;58(3):704-710.
150. Wang J, Olak J, Ultmann RE, Ferguson MK. Assessment of pulmonary complications after lung resection. *Ann Thorac Surg.* 1999;67(5):1444-1447.
151. Bolliger CT, Jordan P, Solèr M, et al. Exercise capacity as a predictor of postoperative complications in lung resection candidates. *Am J Respir Crit Care Med.* 1995;151(5):1472-1480.
152. Win T, Jackson A, Sharples L, et al. Cardiopulmonary exercise tests and lung cancer surgical outcome. *Chest.* 2005;127(4):1159-1165.
153. Smith TP, Kinasevitz GT, Tucker WY, Spillers WP, George RB. Exercise capacity as a predictor of post-thoracotomy morbidity. *Am Rev Respir Dis.* 1984;129(5):730-734.
154. Birim O, Kappetein AP, Goorden T, van Klaveren RJ, Bogers AJJC. Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancer. *Ann Thorac Surg.* 2005;80(3):1021-1026.
155. Brutsche MH, Spiliopoulos A, Bolliger CT, Licker M, Frey JG, Tschopp JM. Exercise capacity and extent of resection as predictors of surgical risk in lung cancer. *Eur Respir J.* 2000;15(5):828-832.
156. Kozower BD, Sheng SB, O'Brien SM, et al. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. *Ann Thorac Surg.* 2010;90(3):875-881.
157. Win T, Jackson A, Groves AM, Sharples LD, Charman SC, Laroche CM. Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer. *Thorax.* 2006;61(1):57-60.
158. Epstein SK, Faling LJ, Daly BDT, Celli BR. Predicting complications after pulmonary resection. Preoperative exercise testing vs a multifactorial cardiopulmonary risk index. *Chest.* 1993;104(3):694-700.
159. Richter Larsen K, Svendsen UG, Milman N, Brenøe J, Petersen BN. Exercise testing in the preoperative evaluation of patients with bronchogenic carcinoma. *Eur Respir J.* 1997;10(7):1559-1565.
160. Morice RC, Peters EJ, Ryan MB, Putnam JB, Ali MK, Roth JA. Exercise testing in the evaluation of patients at high risk for complications from lung resection. *Chest.* 1992;101(2):356-361.
161. Bolliger CT, Wyser C, Roser H, Solèr M, Perruchoud AP. Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. *Chest.* 1995;108(2):341-348.
162. Kasikcioglu E, Tokar A, Tanju S, et al. Oxygen uptake kinetics during cardiopulmonary exercise testing and postoperative complications in patients with lung cancer. *Lung Cancer.* 2009;66(1):85-88.
163. Saumon G. Pump and circumstances. *Am J Respir Crit Care Med.* 2003;168(12):1408-1409.
164. Brunelli A, Belardinelli R, Pompili C, et al. Minute ventilation-to-carbon dioxide output (VE/VCO<sub>2</sub>) slope is the strongest predictor of respiratory complications and death after pulmonary resection. *Ann Thorac Surg.* 2012;93(6):1802-1806.

165. Ribas J, Díaz O, Barberà JA, et al. Invasive exercise testing in the evaluation of patients at high-risk for lung resection. *Eur Respir J*. 1998;12(6):1429-1435.
166. Bolliger CT, Solèr M, Stulz P, et al. Evaluation of high-risk lung resection candidates: pulmonary haemodynamics versus exercise testing. A series of five patients. *Respiration*. 1994;61(4):181-186.
167. Wang JS, Abboud RT, Evans KG, Finley RJ, Graham BL. Role of CO diffusing capacity during exercise in the preoperative evaluation for lung resection. *Am J Respir Crit Care Med*. 2000;162(4 Pt 1):1435-1444.
168. Vidal Melo MF, Barazani K, Winga E, Johnson RL. Estimate of pulmonary diffusing capacity for oxygen during exercise in humans from routine O(2) and CO(2) measurements. *Clin Physiol Funct Imaging*. 2004;24(1):46-57.
169. Swinburn CR, Wakefield JM, Jones PW. Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease. *Thorax*. 1985;40(8):581-586.
170. Pollock M, Roa J, Benditt J, Celli B. Estimation of ventilatory reserve by stair climbing. A study in patients with chronic airflow obstruction. *Chest*. 1993;104(5):1378-1383.
171. Bolton JWR, Weiman DS, Haynes JL, Hornung CA, Olsen GN, Almond CH. Stair climbing as an indicator of pulmonary function. *Chest*. 1987;92(5):783-788.
172. Brunelli A, Al Refai M, Monteverde M, Borri A, Salati M, Fianchini A. Stair climbing test predicts cardiopulmonary complications after lung resection. *Chest*. 2002;121(4):1106-1110.
173. Olsen GN, Bolton JWR, Weiman DS, Hornung CA. Stair climbing as an exercise test to predict the postoperative complications of lung resection. Two years' experience. *Chest*. 1991;99(3):587-590.
174. Brunelli A, Xiumé F, Refai M, et al. Peak oxygen consumption measured during the stair-climbing test in lung resection candidates. *Respiration*. 2010;80(3):207-211.
175. Koegelenberg CFN, Diacon AH, Irani S, Bolliger CT. Stair climbing in the functional assessment of lung resection candidates. *Respiration*. 2008;75(4):374-379.
176. Toker A, Ziyade S, Bayrak Y, et al. Prediction of cardiopulmonary morbidity after resection for lung cancer: stair climbing test complications after lung cancer surgery. *Thorac Cardiovasc Surg*. 2007;55(4):253-256.
177. Brunelli A, Sabbatini A, Xiumé F, et al. Inability to perform maximal stair climbing test before lung resection: a propensity score analysis on early outcome. *Eur J Cardiothorac Surg*. 2005;27(3):367-372.
178. Brunelli A, Monteverde M, Al Refai M, Fianchini A. Stair climbing test as a predictor of cardiopulmonary complications after pulmonary lobectomy in the elderly. *Ann Thorac Surg*. 2004;77(1):266-270.
179. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. *Chest*. 2001;119(1):256-270.
180. Singh SJ, Morgan MDL, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax*. 1992;47(12):1019-1024.
181. Win T, Jackson A, Groves AM, et al. Relationship of shuttle walk test and lung cancer surgical outcome. *Eur J Cardiothorac Surg*. 2004;26(6):1216-1219.
182. Benzo RP, Sciurba FC. Oxygen consumption, shuttle walking test and the evaluation of lung resection. *Respiration*. 2010;80(1):19-23.
183. Crapo RO, Casaburi R, Coates AL, et al; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111-117.
184. Brunelli APC, Pompili C, Salati M. Low-technology exercise test in the preoperative evaluation of lung resection candidates. *Monaldi Arch Chest Dis*. 2010;73(2):72-78.
185. Turner SE, Eastwood PR, Cecins NM, Hillman DR, Jenkins SC. Physiologic responses to incremental and self-paced exercise in COPD: a comparison of three tests. *Chest*. 2004;126(3):766-773.
186. Ninan M, Sommers KE, Landreneau RJ, et al. Standardized exercise oximetry predicts postpneumonectomy outcome. *Ann Thorac Surg*. 1997;64(2):328-332.
187. Rao V, Todd TRJ, Kuus A, Buth KJ, Pearson FG. Exercise oximetry versus spirometry in the assessment of risk prior to lung resection. *Ann Thorac Surg*. 1995;60(3):603-608.
188. Brunelli A, Refai M, Xiumé F, et al. Oxygen desaturation during maximal stair-climbing test and postoperative complications after major lung resections. *Eur J Cardiothorac Surg*. 2008;31(1):77-82.
189. Varela G, Cordovilla R, Jiménez MF, Novoa N. Utility of standardized exercise oximetry to predict cardiopulmonary morbidity after lung resection. *Eur J Cardiothorac Surg*. 2001;19(3):351-354.
190. Melendez JA, Barrera R. Predictive respiratory complication quotient predicts pulmonary complications in thoracic surgical patients [published correction appears in *Ann Thorac Surg*. 1998;6(6):2164]. *Ann Thorac Surg*. 1998;66(1):224-240.
191. Brunelli A, Fianchini A, Gesuita R, Carle F. POSSUM scoring system as an instrument of audit in lung resection surgery. Physiological and operative severity score for the enumeration of mortality and morbidity. *Ann Thorac Surg*. 1999;67(2):329-331.
192. Ferguson MK, Durkin AE. A comparison of three scoring systems for predicting complications after major lung resection. *Eur J Cardiothorac Surg*. 2003;23(1):35-42.
193. Berrisford R, Brunelli A, Rocco G, Treasure T, Utley M; Audit and guidelines committee of the European Society of Thoracic Surgeons; European Association of Cardiothoracic Surgeons. The European Thoracic Surgery Database project: modelling the risk of in-hospital death following lung resection. *Eur J Cardiothorac Surg*. 2005;28(2):306-311.
194. Falcoz PE, Conti M, Brouchet L, et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. *J Thorac Cardiovasc Surg*. 2007;133(2):325-332.
195. Celli BR. What is the value of preoperative pulmonary function testing? *Med Clin North Am*. 1993;77(2):309-325.
196. Zibrak JD, O'Donnell CR, Marton K. Indications for pulmonary function testing. *Ann Intern Med*. 1990;112(10):763-771.
197. Tisi GM. Preoperative evaluation of pulmonary function. Validity, indications, and benefits. *Am Rev Respir Dis*. 1979;119(2):293-310.
198. Stein M, Koota GM, Simon M, Frank HA. Pulmonary evaluation of surgical patients. *JAMA*. 1962;181(9):765-770.
199. Kearney DJ, Lee TH, Reilly JJ, DeCamp MM, Sugarbaker DJ. Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. *Chest*. 1994;105(3):753-759.
200. Harpole DH, Liptay MJ, DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. *Ann Thorac Surg*. 1996;61(3):977-982.
201. Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. *Am J Respir Crit Care Med*. 2003;167(9):1287.



202. Olsen GN, Block AJ, Tobias JA. Prediction of postpneumectomy pulmonary function using quantitative macroaggregate lung scanning. *Chest*. 1974;66(1):13-16.
203. Nezu K, Kushibe K, Tojo T, Takahama M, Kitamura S. Recovery and limitation of exercise capacity after lung resection for lung cancer. *Chest*. 1998;113(6):1511-1516.
204. Bolliger CT, Jordan P, Solèr M, et al. Pulmonary function and exercise capacity after lung resection. *Eur Respir J*. 1996;9(3):415-421.
205. Pelletier C, Lapointe L, LeBlanc P. Effects of lung resection on pulmonary function and exercise capacity. *Thorax*. 1990;45(7):497-502.
206. Ali MK, Ewer MS, Atallah MR, et al. Regional and overall pulmonary function changes in lung cancer. Correlations with tumor stage, extent of pulmonary resection, and patient survival. *J Thorac Cardiovasc Surg*. 1983;86(1):1-8.
207. Sarna L, Evangelista L, Tashkin D, et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. *Chest*. 2004;125(2):439-445.
208. Rivera MP, Detterbeck FC, Socinski MA, et al. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. *Chest*. 2009;135(6):1588-1595.
209. Leo F, Solli P, Spaggiari L, et al. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? *Ann Thorac Surg*. 2004;77(1):260-265.
210. Takeda S, Funakoshi Y, Kadota Y, et al. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication? *Ann Thorac Surg*. 2006;82(1):232-236.
211. Margaritora S, Cesario A, Cusumano G, et al. Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery. *J Thorac Cardiovasc Surg*. 2010;139(6):1457-1463.
212. Cerfolio RJ, Talati A, Bryant AS. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications. *Ann Thorac Surg*. 2009;88(3):930-935.
213. Fujita S, Katakami N, Takahashi Y, et al. Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer. *Eur J Cardiothorac Surg*. 2006;29(6):896-901.
214. Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med*. 2003;348(21):2059-2073.
215. Duarte IG, Gal AA, Mansour KA, Lee RB, Miller JJ. Pathologic findings in lung volume reduction surgery. *Chest*. 1998;113(3):660-664.
216. Keller CA, Naunheim KS, Osterloh J, Espiritu J, McDonald JW, Ramos RR. Histopathologic diagnosis made in lung tissue resected from patients with severe emphysema undergoing lung volume reduction surgery. *Chest*. 1997;111(4):941-947.
217. McKenna RJ Jr, Fischel RJ, Brenner M, Gelb AF. Combined operations for lung volume reduction surgery and lung cancer. *Chest*. 1996;110(4):885-888.
218. Vaughan P, Oey I, Nakas A, Martin-Ucar A, Edwards J, Waller D. Is there a role for therapeutic lobectomy for emphysema? *Eur J Cardiothorac Surg*. 2007;31(3):486-490.
219. DeMeester SR, Patterson GA, Sundaresan RS, Cooper JD. Lobectomy combined with volume reduction for patients with lung cancer and advanced emphysema. *J Thorac Cardiovasc Surg*. 1998;115(3):681-688.
220. Ojo TC, Martinez F, Paine R III, et al. Lung volume reduction surgery alters management of pulmonary nodules in patients with severe COPD. *Chest*. 1997;112(6):1494-1500.
221. DeRose JJ Jr, Argenziano M, El-Amir N, et al. Lung reduction operation and resection of pulmonary nodules in patients with severe emphysema. *Ann Thorac Surg*. 1998;65(2):314-318.
222. Rozenshtein A, White CS, Austin JHM, Romney BM, Protopapas Z, Krasna MJ. Incidental lung carcinoma detected at CT in patients selected for lung volume reduction surgery to treat severe pulmonary emphysema. *Radiology*. 1998;207(2):487-490.
223. Allen GM, DeRose JJ Jr. Pulmonary nodule resection during lung volume reduction surgery. *AORN*. 1997;66(5):808-810,812,814.
224. Choong CK, Meyers BF, Battafarano RJ, et al. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. *J Thorac Cardiovasc Surg*. 2004;127(5):1323-1331.
225. Pompeo E, De Dominicis E, Ambrogi V, Mineo D, Elia S, Mineo TC. Quality of life after tailored combined surgery for stage I non-small-cell lung cancer and severe emphysema. *Ann Thorac Surg*. 2003;76(6):1821-1827.
226. Nakajima T, Sekine Y, Yamada Y, et al. Long-term surgical outcome in patients with lung cancer and coexisting severe COPD. *Thorac Cardiovasc Surg*. 2009;57(6):339-342.
227. Mentzer SJ, Swanson SJ. Treatment of patients with lung cancer and severe emphysema. *Chest*. 1999;116(suppl 6):477S-479S.
228. Barrera R, Shi WJ, Amar D, et al. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. *Chest*. 2005;127(6):1977-1983.
229. Groth SS, Whitson BA, Kuskowski MA, Holmstrom AM, Rubins JB, Kelly RF. Impact of preoperative smoking status on postoperative complication rates and pulmonary function test results 1-year following pulmonary resection for non-small cell lung cancer. *Lung Cancer*. 2009;64(3):352-357.
230. Nakagawa M, Tanaka H, Tsukuma H, Kishi Y. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. *Chest*. 2001;120(3):705-710.
231. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. *Ann Thorac Surg*. 2009;88(2):362-370.
232. Nakamura H, Haruki T, Adachi Y, Fujioka S, Miwa K, Taniguchi Y. Smoking affects prognosis after lung cancer surgery. *Surg Today*. 2008;38(3):227-231.
233. Slatore CG, Au DH, Hollingworth W. Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer. *J Thorac Oncol*. 2009;4(4):499-504.
234. Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5)(suppl):e61S-e77S.
235. Colt HC, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the lung cancer patient after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5)(suppl):e437S-e454S.
236. Ries AL, Make BJ, Lee SM, et al; National Emphysema Treatment Trial Research Group. The effects of pulmonary

- rehabilitation in the national emphysema treatment trial. *Chest*. 2005;128(6):3799-3809.
237. Weinstein H, Bates AT, Spaltro BE, Thaler HT, Steingart RM. Influence of preoperative exercise capacity on length of stay after thoracic cancer surgery. *Ann Thorac Surg*. 2007;84(1):197-202.
238. Bobbio A, Chetta A, Ampollini L, et al. Preoperative pulmonary rehabilitation in patients undergoing lung resection for non-small cell lung cancer. *Eur J Cardiothorac Surg*. 2008;33(1):95-98.
239. Jones LW, Eves ND, Peterson BL, et al. Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. *Cancer*. 2008;113(12):3430-3439.
240. Cesario A, Ferri L, Galetta D, et al. Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer. *Lung Cancer*. 2007;57(2):175-180.
241. Riesenberger H, Lübke AS. In-patient rehabilitation of lung cancer patients—a prospective study. *Support Care Cancer*. 2010;18(7):877-882.
242. Arbane G, Tropman D, Jackson D, Garrod R. Evaluation of an early exercise intervention after thoracotomy for non-small cell lung cancer (NSCLC), effects on quality of life, muscle strength and exercise tolerance: randomised controlled trial. *Lung Cancer*. 2011;71(2):229-234.
243. Spruit MA, Janssen PP, Willemssen SCP, Hochstenbag MMH, Wouters EFM. Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study. *Lung Cancer*. 2006;52(2):257-260.
244. Kaneda H, Saito Y, Okamoto M, Maniwa T, Minami K, Imamura H. Early postoperative mobilization with walking at 4 hours after lobectomy in lung cancer patients. *Gen Thorac Cardiovasc Surg*. 2007;55(12):493-498.